Adhera Therapeutics (ATRX) 10-K 15 Apr 22 2021 FY Annual report Financial data

Cover

Cover - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Apr. 14, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	000-13789
Entity Registrant Name	ADHERA THERAPEUTICS, INC.
Entity Central Index Key	0000737207
Entity Tax Identification Number	11-2658569
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	8000 Innovation Parkway
Entity Address, City or Town	Baton Rouge
Entity Address, State or Province	LA
Entity Address, Postal Zip Code	70820
City Area Code	(919)
Local Phone Number	518-3748
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float				$ 0.8
Entity Common Stock, Shares Outstanding			17,293,237
Documents Incorporated by Reference	Portions of the registrant’s definitive proxy statement for its 2022 Annual Meeting of Stockholders are incorporated by reference in Items 10, 11, 12, 13, and 14 of Part III of this Annual Report on Form 10-K.
ICFR Auditor Attestation Flag	false
Auditor Firm ID	106	23
Auditor Name	SALBERG & COMPANY, P.A.	Baker Tilly US LLP
Auditor Location	Boca Raton, Florida	Los Angeles, California

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets
Cash	$ 76	$ 1
Prepaid expenses	120
Total current assets	196	1
Total assets	196	1
Current liabilities
Accounts payable	2,309	2,257
Due to related parties	46	4
Accrued expenses	3,110	2,112
Accrued dividends	5,477	4,083
Term loan	5,677	5,677
Convertible notes payable, net	986	641
Derivative liability	7,697
Total current liabilities	25,302	14,774
Total liabilities	25,302	14,774
Commitments and contingencies (Note 9)
Stockholders’ deficit
Preferred stock
Common stock, $0.006 par value; 180,000,000 shares authorized, 16,998,836 and 11,112,708 shares issued and outstanding as of December 31, 2021 and 2020, respectively	102	67
Additional paid-in capital	27,809	29,772
Accumulated deficit	(53,017)	(44,612)
Total stockholders’ deficit	(25,106)	(14,773)
Total liabilities and stockholders’ deficit	196	1
Series C Convertible Preferred Stock [Member]
Stockholders’ deficit
Preferred stock
Series D Convertible Preferred Stock [Member]
Stockholders’ deficit
Preferred stock
Series E Convertible Preferred Stock [Member]
Stockholders’ deficit
Preferred stock
Series F Convertiable Preferred Stock [Member]
Stockholders’ deficit
Preferred stock
Series G Convertiable Preferred Stock [Member]
Stockholders’ deficit
Preferred stock

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	100,000	100,000
Common Stock, Par or Stated Value Per Share	$ 0.006	$ 0.006
Common Stock, Shares Authorized	180,000,000	180,000,000
Common stock, shares issued	16,998,836	11,112,708
Common Stock, Shares, Outstanding	16,998,836	11,112,708
Series C Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,200	1,200
Preferred stock, shares issued	100	100
Preferred stock, shares outstanding	100	100
Preferred stock, liquidation preference value	$ 510,000	$ 510,000
Series D Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	220	220
Preferred stock, shares issued	40	40
Preferred stock, shares outstanding	40	40
Preferred stock, liquidation preference value	$ 12,000	$ 12,000
Series E Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	3,500	3,500
Preferred stock, shares issued	3,326	3,458
Preferred stock, shares outstanding	3,326	3,458
Preferred stock, liquidation preference value	$ 21,618,999	$ 21,618,999
Series F Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	2,200	2,200
Preferred stock, shares issued	358	361
Preferred stock, shares outstanding	358	361
Preferred stock, liquidation preference value	$ 2,277,509	$ 2,277,509
Series G Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	6,000	6,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Preferred stock, liquidation preference value	$ 5,000	$ 5,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating expenses
Sales and marketing	$ 17	$ 839
General and administrative	657	1,198
Total operating expenses	674	2,037
Loss from operations	(674)	(2,037)
Other income (expense)
Interest expense, net	(1,035)	(935)
Other income		45
Initial and change in fair value of derivative liability	(4,103)
Loss on extinguishment of debt	(141)
Amortization of debt discount	(398)	(839)
Total other income (expense)	(5,677)	(1,729)
Loss before provision for income taxes	(6,351)	(3,766)
Provision for income taxes
Net loss	(6,351)	(3,766)
Accrued and deemed dividends	(2,054)	(1,540)
Net Loss Applicable to Common Stockholders	$ (8,405)	$ (5,306)
Net loss per share - Common Stockholders, basic and diluted	$ (0.65)	$ (0.49)
Weighted average shares outstanding, basic and diluted	13,003,658	10,876,513

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit - USD ($) $ in Thousands	Preferred Stock [Member]Series C Preferred Stock [Member]	Preferred Stock [Member]Series D Preferred Stock [Member]	Preferred Stock [Member]Series E Preferred Stock [Member]	Preferred Stock [Member]Series F Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019					$ 65	$ 29,375	$ (39,327)	$ (9,887)
Balance, shares at Dec. 31, 2019	100	40	3,478	361	10,869,530
Accrued dividends							(1,540)	(1,540)
Issuance of warrants and common stock with convertible notes						294		294
Issuance of common stock for Series E conversion					$ 2		21	23
Issuance of common stock for Series E conversion, shares			(20)		243,178
Share based compensation						8		8
Beneficial conversion feature - convertible notes						95		95
Net loss							(3,766)	(3,766)
Balance, shares at Dec. 31, 2020	100	40	3,458	361	11,112,708
Ending balance, value at Dec. 31, 2020					$ 67	29,772	(44,612)	(14,773)
Issuance of warrants and common stock with convertible notes					4	316		320
Issuance of common stock for Series E conversion					$ 10	106		116
Issuance of common stock for Series E conversion, shares			(132)		1,550,989
Net loss							(6,351)	(6,351)
Accrued and deemed dividend						541	(2,054)	(1,513)
Reclassification of derivative from equity						(3,462)		(3,462)
Issuance of common stock for cashless exercise of warrant					$ 1	(1)
Issuance of common stock for cashless exercise of warrants, shares					206,798
Issuance of warrants and common stock with convertible notes, shares					715,285
Issuance of common stock for convertible note conversions					$ 20	534		554
Issuance of common stock for convertible note conversion, shares					3,366,012
Issuance of common stock for Series F conversion						3		3
Issuance of common stock for Series F conversion, shares				(3)	37,043
Balance, shares at Dec. 31, 2021	100	40	3,326	358	16,988,836
Ending balance, value at Dec. 31, 2021					$ 102	$ 27,809	$ (53,017)	$ (25,106)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash Flows Used in Operating Activities:
Net loss	$ (6,351,000)	$ (3,766,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Share based compensation		8,000
Amortization of debt discount	398,000	839,000
Accrued interest expense	1,035,000	935,000
Derivative expense	4,103,000
Loss on debt extinguishment	141,000
Changes in operating assets and liabilities:
Prepaid expenses	(120,000)	370,000
Accounts payable	94,000	854,000
Accrued expenses	35,000	172,000
Net Cash Used in Operating Activities	(665,000)	(588,000)
Cash Flows Provided by Financing Activities:
Proceeds from notes payable, net of original issue discounts	840,000	653,000
Notes payable issuance costs	(101,000)	(114,000)
Net Cash Provided by Financing Activities	739,000	539,000
Net increase (decrease) in cash	74,000	(49,000)
Cash – Beginning of Year	1,000	50,000
Cash - End of Year	75,000	1,000
Non-cash Investing and Financing Activities:
Issuance of common stock for conversion of Series E Preferred	116,000	23,000
Issuance of common stock for conversion of Series F Preferred	3,000
Debt discounts for issuance costs, warrants and derivatives	320,000	294,000
Issuance of common stock for conversion of convertible notes	554,000
Reclassification of derivative liability	3,462,000
Accrued and deemed dividends	2,054,000	1,540,000
Beneficial conversion feature		$ 95,000

Organization and Business Opera

Organization and Business Operations	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business Operations	Note 1 – Organization and Business Operations Adhera Therapeutics, Inc. and its wholly-owned subsidiaries, MDRNA Research, Inc. (“MDRNA”), Cequent Pharmaceuticals, Inc. (“Cequent”), Atossa Healthcare, Inc. (“Atossa”), and IThenaPharma, Inc. (“IThena”) (collectively “Adhera,” or the “Company”), is an emerging specialty biotech company that, to the extent that resources and opportunities become available, is strategically evaluating its focus including a return to a drug discovery and development company. On July 28, 2021, we as licensee and Melior Pharmaceuticals II, LLC entered into an exclusive license agreement for the development, commercialization and exclusive license of MLR-1019. MLR-1019 is being developed as a new class of therapeutic for Parkinson’s disease (PD) and is, to the best of our knowledge, the only drug candidate today to address both movement and non-movement aspects of PD. Under the Agreement, we were granted an exclusive license to use the MP Patents and know-how to develop products in consideration for cash payments upon meeting certain performance milestones as well as a royalty of 5% of gross sales. On August 20, 2021, we as licensee entered into an exclusive license agreement with Melior Pharmaceuticals I, Inc. for the development, commercialization and exclusive license of MLR-1023. MLR-1023 is being developed as a novel therapeutic for Type 1 diabetes. On October 20, 2021, we as licensee expanded the exclusive licensing agreement with Melior Pharmaceuticals I, Inc. to include two additional clinical indications for Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation. To the extent that resources have been available, the Company has continued to work with its advisors in an effort to restructure our company and to identify potential strategic transactions to enhance the value of our company as such opportunities arise, including potential transactions and capital raising initiatives involving the assets relating to our legacy RNA interference programs, as well as business combination transactions with operating companies. There can be no assurance that the Company will be successful at identifying any such transactions, that it will continue to have sufficient resources to actively attempt to identify such transactions, or that such transactions will be available upon terms acceptable to us or at all. If the Company does not complete any significant strategic transactions, or raise substantial additional capital, in the immediate future, it is likely that the Company will discontinue all operations and seek bankruptcy protection.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The summary of significant accounting policies presented below is designed to assist in understanding the Company’s financial statements. Such financial statements and accompanying notes are the representations of Company’s management, who is responsible for their integrity and objectivity. Principles of Consolidation The consolidated financial statements include the accounts of Adhera Therapeutics, Inc. and the wholly-owned subsidiaries, Ithena, Cequent, MDRNA, and Atossa, and eliminate any inter-company balances and transactions. All wholly-owned subsidiaries of Adhera Therapeutics, Inc. are inactive. Going Concern and Management’s Liquidity Plans The accompanying consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. As of December 31, 2021, the Company had cash and cash equivalents of approximately $ 76,000 25.1 The Company has incurred recurring losses and negative cash flows from operations since inception and has funded its operating losses through the sale of common stock, preferred stock, warrants to purchase common stock, convertible notes and secured promissory notes. The Company incurred a net loss of approximately $ 6.4 million for the year ended December 31, 2021 and used cash in operating activities of approximately $ 665,000 53.0 million as of December 31, 2021. In addition, to the extent that the Company continues its business operations, the Company anticipates that it will continue to have negative cash flows from operations, at least into the near future. However, the Company cannot be certain that it will be able to obtain such funds required for its our operations at terms acceptable to the Company or at all. General market conditions, as well as market conditions for companies in the Company’s financial and business position, as well as the ongoing issue arising from the COVID-19 pandemic, may make it difficult for the Company to seek financing from the capital markets, and the terms of any financing may adversely affect the holdings or the rights of its stockholders. If the Company is unable to obtain additional financing in the future, there may be a negative impact on the financial viability of the Company. The Company plans to increase working capital by managing its cash flows and expenses, divesting development assets and raising additional capital through private or public equity or debt financing. There can be no assurance that such financing or partnerships will be available on terms which are favorable to the Company or at all. While management of the Company believes that it has a plan to fund ongoing operations, there is no assurance that its plan will be successfully implemented. Failure to raise additional capital through one or more financings, divesting development assets or reducing discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this Report. The consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties. Summary of Significant Accounting Policies Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. As of December 31, 2021, the Company had approximately $ 76,000 in cash equivalents. The Company deposits its cash with major financial institutions and may at times exceed the federally insured limit. At December 31, 2021, the Company’s cash balance did not exceed the federal insurance limit. Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include accruals related to our operating activity including legal and other consulting expenses, the fair value of non-cash equity-based issuances, the fair value of derivative liabilities, and the valuation allowance on deferred tax assets. Actual results could differ materially from such estimates under different assumptions or circumstances. Fair Value of Financial Instruments The Company considers the fair value of cash, accounts payable, debt, and accrued expenses not to be materially different from their carrying value. These financial instruments have short-term maturities. We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. As of December 31, 2021, the Company measured conversion features on outstanding convertible notes and warrants as a derivative liability using significant unobservable prices that are based on little or no verifiable market data, which is Level 3 in the fair value hierarchy, resulting in a fair value estimate of approximately $ 7.7 million. The value of the derivative liability as of December 31, 2021, was determined by using the binomial lattice model using the following inputs: 0.069 % to 1.26 % risk free rate, volatility of 255 % to 399 % and time to maturity of 0 - 0.60 years. There were no liabilities or assets measured at fair value on a non-recurring basis as of December 31, 2021, and there were no liabilities or assets measured at fair value on a recurring or non-recurring basis as of December 31, 2020. Schedule of Fair Value Measurements (in thousands) (Level 1) (Level 2) (Level 3) Total Fair Value Measurements at December 31, 2021 Quoted Prices in Active Markets for Identical Assets Other Observable Inputs Significant Unobservable Inputs (in thousands) (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 7,697 $ 7,697 Total $ - $ - $ 7,697 $ 7,697 A roll forward of the level 3 valuation financial instruments is as follows: Schedule of Roll Forward of Level 3 Financial Instruments Year Ended December 31, 2021 (In thousands) Warrants Notes Total Balance at December 31, 2020 $ — $ — $ — Initial valuation of derivative liabilities included in debt discount — 377 377 Initial valuation of derivative liabilities included in derivative expense 246 1,348 1,594 Reclassification of derivative liabilities gain to loss on debt extinguishment (52 ) (193 ) (245 ) Reclass from additional paid-in capital 3,107 355 3,462 Change in fair value included in derivative expense 2,035 474 2,509 Balance at December 31, 2021 $ 5,336 $ 2,361 $ 7,697 ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding equity instruments. Convertible Debt and Warrant Accounting Debt with warrants In accordance with ASC Topic 470-20-25, when the Company issues debt with warrants, the Company treats the relative fair value of the warrants as a debt discount, recorded as a contra-liability against the debt, and amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations. The offset to the contra-liability is recorded as additional paid in capital in the Company’s consolidated balance sheets if the warrants are not treated as a derivative. The Company determines the fair value of the warrants using the Black-Scholes Option Pricing Model (“Black-Scholes”), the binomial model or the Monte Carlo Method based upon the underlying conversion features of the debt and then computes and records the relative fair value as a debt discount. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations. Convertible debt – derivative treatment When the Company issues debt with a conversion feature, it first assesses whether the conversion feature meets the requirements to be accounted for as stock settled debt. If it does not meet those requirements then it is assessed on whether the conversion feature should be bifurcated and treated as a derivative liability, as follows: a) one or more underlyings, typically the price of our common stock; b) one or more notional amounts or payment provisions or both, generally the number of shares upon conversion; c) no initial net investment, which typically excludes the amount borrowed; and d) net settlement provisions, which in the case of convertible debt generally means the stock received upon conversion can be readily sold for cash. An embedded equity-linked component that meets the definition of a derivative does not have to be separated from the host instrument if the component qualifies for the scope exception for certain contracts involving an issuer’s own equity. The scope exception applies if the contract is both a) indexed to its own stock; and b) classified in stockholders’ equity in its statement of financial position. Convertible debt – beneficial conversion feature Prior to the Company’s adoption of ASU No. 2020-06, Debt—Debt with Conversion and Other Options Derivatives and Hedging—Contracts in Entity’s Own Equity Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity If the conversion feature does not qualify for either the derivative treatment or as a BCF, the convertible debt is treated as traditional debt. Recently Issued Accounting Pronouncements Recently Adopted In January 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-04, Intangibles-Goodwill and Other (Topic 350) (“ASU 2017-04”), which will simplify the goodwill impairment calculation by eliminating Step 2 from the current goodwill impairment test. The new standard does not change how a goodwill impairment is identified. The Company will continue to perform its quantitative goodwill impairment test by comparing the fair value of its reporting unit to its carrying amount, but if the Company is required to recognize a goodwill impairment charge, under the new standard, the amount of the charge will be calculated by subtracting the reporting unit’s fair value from its carrying amount. Under the current standard, if the Company is required to recognize a goodwill impairment charge, Step 2 requires it to calculate the implied value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination and the amount of the charge is calculated by subtracting the reporting unit’s implied fair value of goodwill from the goodwill carrying amount. The standard was effective January 1, 2020. The adoption of ASU 2017-04 did not have a material impact on the Company’s historical consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which will simplify the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts on an entity’s own equity. Specifically, the new standard will remove the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It will also remove certain settlement conditions that are currently required for equity contracts to qualify for the derivative scope exception and will simplify the diluted earnings per share calculation for convertible instruments. ASU 2020-06 will be effective January 1, 2022, for the Company and may be applied using a full or modified retrospective approach. Early adoption is permitted, but no earlier than January 1, 2021, for the Company. The Company adopted ASU No. 2020-06 on January 1, 2021. Management determined such adoption did not have a material impact on the overall stockholders’ equity (deficit) in the Company’s consolidated financial statements. Not Yet Adopted In May 2021, FASB issued ASU 2021-04: Earnings Per Share (Topic 260), Debt— Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40), to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in ASU 2021-04 provide the following guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic: 1. An entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as an exchange of the original instrument for a new instrument. 2. An entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as follows: a. For a modification or an exchange that is a part of or directly related to a modification or an exchange of an existing debt instrument or line-of-credit or revolving-debt arrangements (hereinafter, referred to as a “debt” or “debt instrument”), as the difference between the fair value of the modified or exchanged written call option and the fair value of that written call option immediately before it is modified or exchanged. Specifically, an entity should consider: i. An increase or a decrease in the fair value of the modified or exchanged written call option in applying the 10 percent cash flow test and/or calculating the fees between debtor and creditor in accordance with Subtopic 470-50, Debt—Modifications and Extinguishments. ii. An increase (but not a decrease) in the fair value of the modified or exchanged written call option in calculating the third-party costs in accordance with Subtopic 470-50. b. For all other modifications or exchanges, as the excess, if any, of the fair value of the modified or exchanged written call option over the fair value of that written call option immediately before it is modified or exchanged. 3. An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange on the basis of the substance of the transaction, in the same manner as if cash had been paid as consideration, as follows: a. A financing transaction to raise equity. The effect should be recognized as an equity issuance cost in accordance with the guidance in Topic 340, Other Assets and Deferred Costs. b. A financing transaction to raise or modify debt. The effect should be recognized as a cost in accordance with the guidance in Topic 470, Debt, and Topic 835, Interest. c. Other modifications or exchanges that are not related to financings or compensation for goods or services or other exchange transactions within the scope of another Topic. The effect should be recognized as a dividend. For entities that present EPS in accordance with Topic 260, that dividend should be an adjustment to net income (or net loss) in the basic EPS calculation. An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option to compensate for goods or services in accordance with the guidance in Topic 718, Compensation—Stock Compensation. In a multiple-element transaction (for example, one that includes both debt financing and equity financing), the total effect of the modification should be allocated to the respective elements in the transaction. The amendments in ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt the amendments in ASU 2021-04 in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company is evaluating the impact of the revised guidance and believes that it will not have a significant impact on its financial statements. Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures. Net Loss per Common Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. Potentially dilutive securities which include outstanding warrants, stock options, convertible notes and preferred stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. For all periods presented, basic and diluted net loss were the same. The following table presents the computation of net loss per share (in thousands, except share and per share data): Schedule of Earnings Per Share, Basic and Diluted (in thousands except share and per share data) 2021 2020 December 31, (in thousands except share and per share data) 2021 2020 Numerator Net loss $ (6,351 ) $ (3,766 ) Preferred stock dividends (2,054 ) (1,540 ) Net Loss allocable to common stockholders $ (8,405 ) $ (5,306 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 13,003,658 10,876,513 Net loss per share of common stock, basic and diluted Net loss per share, basic and diluted $ (0.65 ) $ (0.49 ) The following number of shares have been excluded from diluted net (loss) since such inclusion would be anti-dilutive: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share 2021 2020 Year Ended December 31, 2021 2020 Stock options outstanding 384,050 391,350 Convertible notes 48,696,732 33,658,590 Warrants 74,625,139 78,181,855 Series C Preferred Stock 66,667 66,667 Series D Preferred Stock 50,000 50,000 Series E Preferred Stock 43,240,749 42,055,232 Series F Preferred Stock 4,555,010 4,303,767 Total 171,618,347 158,707,461 As of December 31, 2021, the Company’s fully diluted common stock equivalents exceeded the 180,000,000 Stock-Based Compensation The Company applies the provisions of ASC 718, Compensation—Stock Compensation (“ASC 718”) For stock options issued, the Company estimates the grant date fair value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised if and when a forfeiture becomes probable. Income Taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss and credit carry forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates.

Prepaid Expenses

Prepaid Expenses	12 Months Ended
	Dec. 31, 2021
Prepaid Expenses
Prepaid Expenses	Note 3 – Prepaid Expenses As of December 31, 2021, prepaid expenses totaled approximately $ 120,000 no

Notes Payable and Convertible P

Notes Payable and Convertible Promissory Notes	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Notes Payable and Convertible Promissory Notes	Note 4 – Notes Payable and Convertible Promissory Notes 2019 Term Loan During 2019, the Company entered into term loan subscription agreements with certain accredited investors, pursuant to which the Company issued secured promissory notes in the aggregate principal amount of approximately $ 5.7 707,000 The promissory notes accrued interest at a rate of 12 15 The unpaid principal balance of the notes, plus accrued and unpaid interest thereon, matured on June 28, 2020 The Company recognized approximately $ 1.2 million in interest expense related to the 2019 Term Loan for the year ended December 31, 2020 including $ 347,000 related to the amortization of debt issuances costs. The Company recognized approximately $ 852,000 in interest expense related to the notes for the year ended December 31, 2021. As of December 31, 2021, the debt discount and issuance costs for this term loan were fully amortized. As of December 31, 2021, the Company had approximately $ 2.0 million of accrued interest on the notes included in accrued expenses and remains in default on the repayment of approximately $ 5.7 million in principal and $ 2.0 Convertible Promissory Notes The following table summarizes the Company’s outstanding convertible notes as of December 31, 2021, and December 31, 2020: Schedule of Convertible Promissory Notes (in thousands) December 31, 2021 December 31, 2020 Convertible Notes $ 1,516 $ 720 Unamortized discounts (530 ) (79 ) Convertible Notes Payable $ 986 $ 641 Eight convertible notes with outstanding principal of approximately $ 1.3 million were in default as of the issuance date of this Report. Secured Convertible Promissory Note – February 2020 On February 5, 2020, the Company entered into a Securities Purchase Agreement with accredited investors and issued the investors, (i) original issue discount Convertible Promissory Notes with a principal of $ 550,500 10 499,950 The Convertible Notes matured on August 5, 2020 . Prior to default, interest accrued to the Holders on the aggregate unconverted and then outstanding principal amount of the Notes at the rate of 10 % per annum, calculated on the basis of a 360-day year and accrues daily. On June 15, 2020, the Company defaulted on certain covenants in the 2020 term loan and the interest rate reset to the default rate of 18 %. Until the Convertible Notes are no longer outstanding, the Convertible Notes are convertible, in whole or in part, at any time, and from time to time, into shares of Common Stock at the option of the noteholder. The conversion price is the lower of: (i) $ 0.50 70 60 0.05 The exercise price of the Warrants shall be equal to the conversion price of the Convertible Notes, provided, that on the date that the Convertible Notes are no longer outstanding, the exercise price shall be fixed at the conversion price of the Convertible Notes on such date, with the exercise price of the Warrants thereafter (and the number of shares of Common Stock issuable upon the exercise thereof) being subject to adjustment as set forth in the Warrants. The warrants have a 5 The Company recorded a discount related to the Warrants of approximately $ 322,000 , which includes an allocation of original issue discount (“OID”) and issue costs of $ 30,000 and $ 53,000 based on the relative fair value of the instruments as determined by using the Monte-Carlo simulation model. The Company also recorded the remaining debt discount related to the convertible debt OID of approximately $ 21,000 and debt issuance costs of $ 38,000 using the relative fair value method to be amortized as interest expense over the term of the loan using the straight-line method. Total discounts recorded were approximately $ 381,000 . The Company recognized $ 75,000 381,000 38,000 96,000 On March 19, 2021, the holder of the Convertible Note converted $ 25,900 518,000 On July 29, 2021, the holder of the Convertible Note converted $ 27,500 550,000 On August 16, 2021, the holder of the Convertible Note converted $ 25,000 500,000 On September 13, 2021, the holder of the Convertible Note converted $ 32,500 650,000 On October 4, 2021, the holder of the Convertible Note converted $ 26,250 525,000 On November 29, 2021, the holder of the Convertible Note converted $ 31,150 623,012 The total note principal and interest converted during the year ended December 31, 2021, was $ 168,300 3,366,012 554,000 386,000 245,000 245,000 141,000 As of December 31, 2021, the Company had accrued interest on the February 2020 Convertible Note of approximately $ 101,000 As of December 31, 2021, the Company remains in default on the repayment of remaining principal of $ 457,359 and accrued interest on the February 2020 Convertible Notes. Upon demand for repayment at the election of the holder, the holder of the Convertible Note is due 140 % of the aggregate of outstanding principal, interest, and other expenses due in respect of this Convertible Note. The 40% premium will be recorded once a demand occurs. Secured Convertible Promissory Note – June 2020 On June 26, 2020, the Company issued to an existing investor in the Company a 10 % original issue discount Senior Secured Convertible Promissory Note with a principal of $ 58,055 , for a purchase price of $ 52,500 , net of the original issue discount of $ 5,555 . The Convertible Note matured on December 26, 2020 . Prior to default, interest accrued on the aggregate unconverted and then outstanding principal amount of the Note at the rate of 10 % per annum, calculated on the basis of a 360-day year. The Company incurred approximately $ 14,000 in debt issuance costs. On August 5, 2020, the Company defaulted on certain covenants in the loan and the interest rate reset to the default rate of 18 The Note is convertible, in whole or in part, into shares of common stock of the Company at the option of the noteholder at a conversion price of $ 0.02 65 50,000 203,000 The obligations of the Company under the Note are secured by a senior lien and security interest in all of the assets of the Company and certain of its wholly-owned subsidiaries pursuant to the terms and conditions of a Security Agreement dated June 26, 2020 by the Company in favor of the noteholder. In connection with the issuance of the Note, the holders of the secured promissory notes that the Company issued to select accredited investors between June 28, 2019 and August 5, 2019 in the aggregate principal amount of approximately $ 5.7 For the year ended December 31, 2020, the Company recognized approximately $ 5,000 70,000 14,000 11,000 As of December 30, 2021, the Company remains in default on the repayment of principal of $ 58,055 16,000 140 The 40% premium will be recorded once a demand occurs Secured Convertible Promissory Note – October 2020 On October 30, 2020, the Company issued to an existing investor in and lender to the Company a 10 111,111 100,000 0.07 70 0.05 The obligations of the Company under the note are secured by a senior lien and security interest in all of the assets of the Company. The Company recorded approximately $ 9,000 The interest rate on the note was 10 18 Additionally, the Company issued the noteholder 1,587,301 0.05 952,379 57,000 0.16 262.27 0.92 The Company recorded a discount related to the warrants of approximately $ 66,000 6,000 5,000 45,000 69,000 5,000 4,000 For the year ended December 31, 2020, the Company recognized approximately $ 2,000 in interest expense. For the year ended December 31, 2020, the Company recognized $ 41,300 related to the amortization of debt discount including $ 1,300 of debt issuance costs. For the year ended December 31, 2021, the Company recognized approximately $ 17,000 in interest expense. For the year ended December 31, 2021, the Company recognized $ 79,000 related to the amortization of debt discount including debt issuance costs. As of December 31, 2021, the Company has outstanding principal of $ 111,111 19,000 As of December 31, 2021, the Company remains in default on the repayment of principal and interest on the notes. Upon demand for repayment at the election of the holder, the holder of the note is due 125 The 25% premium will be recorded once a demand occurs Secured Convertible Promissory Note – January 2021 On January 31, 2021, the Company issued to an existing investor in and lender to the Company a 10 52,778 47,500 5,278 0.07 70 The obligations of the Company under the Note are secured by a senior lien and security interest in all assets of the Company. Additionally, the Company issued to the investor 753,968 0.08 0.05 452,372 27,000 0.16 262.27 0.97 The Company recorded approximately $ 2,000 The interest rate on the note was 10 18 The Company recorded a discount related to the warrants of approximately $ 32,000 3,000 1,000 0.45 240.83 one year The Company also recorded a debt discount related to the convertible debt of approximately $ 2,000 1,000 Total discounts recorded including the original issue discount were approximately $ 35,000 For year ended December 31, 2021, the Company recognized approximately $ 6,700 35,000 As of December 31, 2021, the Company has outstanding principal of $ 52,778 on the note, and has recorded approximately $ 6,700 of accrued interest included in accrued expenses on the accompanying balance sheet. As of December 31, 2021, the Company remains in default on the repayment of principal and accrued interest on the notes. Upon demand for repayment at the election of the holder, the holder of the note is due 125 The 25% premium will be recorded once a demand occurs Secured Convertible Promissory Note – April 2021 On April 12, 2021, the Company issued to an accredited investor in and lender to the Company a 10 66,667 60,000 6,667 800,000 five 0.095 The note matured on October 12, 2021 , Prior to default, interest accrued on the aggregate unconverted and then outstanding principal amount of the note at the rate of 10 % per annum, calculated on-the-basis of a 360-day year. On October 12, 2021, the Company defaulted on the note and the interest rate on the note reset to 18 % per annum. The Note is convertible, in whole or in part, at any time, and from time to time, into shares of the common stock of the Company at the option of the noteholder at a conversion price of $ 0.075 70 The Company recorded a discount related to the warrants of approximately $ 34,000 3,700 3,000 0.89 240.64 one year On June 25, 2021, the exercise price of the warrants was adjusted to $ 0.075 213,333 11,000 0.92 247.52 0.96 On November 4, 2021, the Company issued 153,227 250,000 On November 30, 2021, the exercise price of the warrants was adjusted to $ 0.05 based on a note conversion at $ 0.05 and the Company issued an additional 131,667 warrants to the note holder. For the year ended December 31, 2021, the Company recognized approximately $ 6,100 37,500 As of December 31, 2021, the Company has recorded $ 66,667 6,100 As of December 31, 2021, the Company remains in default on the repayment of principal and accrued interest on the notes. Upon demand for repayment at the election of the holder, the holder of the note is due 125 The 25% premium will be recorded once a demand occurs Secured Convertible Promissory Note – June 2021 On June 25, 2021, the Company issued to an accredited investor in and lender to the Company a 5 66,500 63,000 3,500 800,000 three 0.095 76,000 The note matures on June 25, 2022 10 The Note is convertible, in whole or in part, at any time, and from time to time, into shares of the common stock of the Company at the option of the noteholder at a conversion price of $ 0.075 0.08 65 The obligations of the Company under the Note are secured by a senior lien and security interest in all assets of the Company. The Company incurred approximately $ 9,300 The Company also issued 47,547 shares of common stock as a commission fee to the investment banker. The fair value of the common stock which was approximately $ 5,040 was recorded as debt issuance expense. Due to the variability in the conversion price of the Note the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $ 102,823 87,039 15,784 Total discounts recorded were $ 66,500 3,500 9,300 37,916 15,784 0.48 302.11 0.60 On August 11, 2021, the exercise price of the warrants was adjusted to $ 0.075 213,333 25,000 0.81 209 0.57 On October 27, 2021, the Company and the institutional investor who holds the convertible promissory note agreed to extend the maturity date of the note by six months to December 25, 2022 for no consideration. On November 30, 2021, the exercise price of the warrants was adjusted to $ 0.05 0.05 and the Company issued an additional 506,667 warrants to the note holder. For the year ended December 31, 2021, the Company recognized approximately $ 27,800 5,800 At December 31, 2021, the Company has recorded $ 66,500 of outstanding principal and approximately $ 5,700 of accrued interest and $ 38,700 of unamortized discount and issuance expenses. Convertible Promissory Note – August 11, 2021 On August 11, 2021, the Company entered into a Securities Purchase Agreement with an accredited institutional investor pursuant to which the Company issued to the investor its Original Issue Discount Secured Convertible Promissory Note in the principal amount of $ 220,500 800,000 210,000 10,500 100,000 The note matures one year from issuance and absent an event of default provides for an interest rate of 10 % per annum, payable at maturity, and is convertible into common stock of the Company at a price of $ 0.075 per share, subject to anti-dilution adjustments in the event of certain corporate events as set forth in the Note, provided that if the average closing price of the Company’s common stock during any three consecutive trading days is below $0.08, the conversion price shall be reduced to 65 % of the lowest trading price during the 20 consecutive trading days immediately preceding the conversion date. On November 9, 2021, the Company defaulted on certain covenants in the note and the interest rate on the note reset to 24 % per annum. In addition to customary anti-dilution adjustments the Note provides, subject to certain limited exceptions, that if the Company issues any common stock or common stock equivalents, as defined in the Note, at a per share price lower than the conversion price then in effect, the conversion price will be reduced to the per share price at which such shares or common share equivalents were sold. The Warrants are initially exercisable for a period of three years at a price of $ 0.095 The Company incurred approximately $ 30,000 The Company also issued 140,000 Due to the variability in the conversion price of the Note the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $ 340,893 234,388 106,505 The Company recorded a total debt discount of $ 220,500 10,500 56,454 30,000 17,041 106,505 The fair value of the warrants on which the relative fair value was based was determined by using a simple binomial lattice model. The assumptions used in the model were a risk-free rate of 0.81 253 one year On November 30, 2021, the exercise price of the warrants was adjusted to $ 0.05 based on a note conversion at $ 0.05 and the Company issued an additional 720,000 warrants to the note holder. For the year ended December 30, 2021, the Company recognized approximately $ 86,400 15,800 At December 31, 2021, the Company has remaining $ 220,500 15,800 134,100 Convertible Promissory Note – August 17, 2021 On August 17, 2021, the Company entered into a Securities Purchase Agreement with an accredited institutional investor pursuant to which the Company issued to the Buyer its Original Issue Discount Secured Convertible Promissory Note in the principal amount of $ 220,500 800,000 210,000 10,500 100,000 The note matures one year 10 0.075 0.08 65 In addition to customary anti-dilution adjustments the Note provides, subject to certain limited exceptions, that if the Company issues any common stock or common stock equivalents, as defined in the Note, at a per share price lower than the conversion price then in effect, the conversion price will be reduced to the per share price at which such shares or common share equivalents were sold. The Warrants are initially exercisable for a period of three years at a price of $ 0.095 The Company incurred approximately $ 30,000 112,601 Due to the variability in the conversion price of the Note, the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $ 398,404 297,833 100,571 The Company recorded a total debt discount of $ 220,500 10,500 62,220 30,000 17,209 100,571 The fair value of the warrants on which the relative fair value was based was determined by using a simple binomial lattice model. The assumptions used in the model were a risk-free rate of 0.77 254 one year On October 27, 2021, the Company and the institutional investor who holds the promissory note agreed to extend the maturity date the notes by six months to February 17, 2023 for no consideration. On November 15, 2021, the Company defaulted on certain covenants in the note and the interest rate on the note reset to 24 On November 30, 2021, the exercise price of the warrants was adjusted to $ 0.05 based on a note conversion at $ 0.05 and the Company issued an additional 720,000 warrants to the note holder. For the year ended December 31, 2021, the Company recognized approximately $ 62,600 15,400 At December 31, 2021, the Company has recorded $ 220,500 15,400 157,900 Convertible Promissory Note – October 4, 2021 On October 4, 2021, the Company entered into a Securities Purchase Agreement (“SPA”) with an institutional investor pursuant to which the Company issued the Buyer a 10 % Convertible Redeemable Note in the principal amount of $ 131,250 and a three-year warrant to purchase 476,190 shares of common stock of the Company for which the Company received proceeds of $ 110,000 . In addition, the Company entered into a Registration Rights Agreement with the Buyer and issued the Buyer 59,523 common shares as a commitment fee. The Note is due October 4, 2022. The Note provides for interest at the rate of 10 % per annum, payable in seven equal monthly payments beginning on August 15, 2022 through the maturity date. The Note is convertible into shares of common stock at any time following the date of cash payment at the Buyer’s option at a conversion price of $ 0.075 per share, subject to certain adjustments. The Warrants are exercisable for three-years from October 4, 2021, at an exercise price of $ 0.095 per share, subject to certain adjustments, which exercise price may be paid on a cashless basis. The aggregate exercise price is $ 45,238 The Company incurred approximately $ 15,000 43,459 Due to the lack of authorized shares, the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $ 564,943 with $ 487,052 charged to derivative expense and $ 77,891 recorded as a debt discount. The Company recorded a total debt discount of $ 131,250 6,250 15,000 32,109 77,891 For the year ended December 31, 2021, the Company recognized approximately $ 32,000 3,200 At December 31, 2021, the Company has recorded $ 131,250 3,200 99,200 Convertible Promissory Note – October 7, 2021 On October 7, 2021, the Company entered into a Securities Purchase Agreement (“SPA”) with an institutional investor pursuant to which the Company issued the Buyer a 10 % Convertible Redeemable Note in the principal amount of $ 131,250 and a three-year warrant to purchase 476,190 shares of common stock of the Company for which the Company received proceeds of $ 110,000 . In addition, the Company entered into a Registration Rights Agreement with the Buyer and issued the Buyer 59,523 common shares as a commitment fee and an additional 52,632 shares as a commission to the broker. The Note is due October 7, 2022. The Note provides for interest at the rate of 10 0.075 The Warrants are exercisable for three-years from October 7, 2021, at an exercise price of $ 0.095 per share, subject to certain adjustments, which exercise price may be paid on a cashless basis. The aggregate exercise price is $ 45,238 The Company incurred approximately $ 15,000 in debt issuance costs. Due to the lack of authorized shares, the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $ 564,184 with $ 487,667 charged to derivative expense and $ 76,517 recorded as a debt discount. The Company recorded a total debt discount of $ 131,250 6,250 33,483 76,517 For the year ended December 31, 2021, the Company recognized approximately $ 30,900 3,100 At December 31, 2021, the Company has recorded $ 131,250 3,100 100,300 Derivative Liabilities Pursuant to Convertible Notes and Warrants In connection with the issuance of the unrelated party convertible notes (collectively referred to as “Notes”) and warrants (collectively referred to as “Warrants”), discussed above, the Company determined that the terms of certain Notes and Warrants contain an embedded conversion options to be accounted for as derivative liabilities due to the holder having the potential to gain value upon conversion and provisions which includes events not within the control of the Company. Due to the fact that the number of shares of common stock issuable exceed the Company’s authorized share limit as of December 31, 2021, the equity environment was tainted and all convertible debentures and warrants were included in the value of the derivative. Accordingly, for existing embedded conversion options and existing warrants that were not previously accounted for as derivatives, the Company reclassified $ 3,462,000 Derivatives and Hedging – Contracts in an Entity’s Own Stock During the year ended December 31, 2021, in connection with the issuance of the Notes and Warrants, on the initial measurement dates, the fair values of the embedded conversion options of approximately $ 2.0 million was recorded as derivative liabilities of which $ 377,269 was allocated as a debt discount and $ 1,593,978 as derivative expense. At the end of the period, the Company revalued the embedded conversion option derivative liabilities. In connection with the initial valuations and these revaluations, the Company recorded a loss from the initial and change in the derivative liabilities fair value of approximately $ 4.1 million for the year ended December 31, 2021. During the year ended December 31, 2021, the fair value of the derivative liabilities was estimated at issuance and at the December 31, 2021, using the Binomial Lattice valuation model with the following assumptions: Schedule of Fair Value of Derivative Liabilities Estimated Issuance and Valuation Mode Dividend rate — % Term (in years) 0.01 to 1 year Volatility 247 % to 412 % Risk-free interest rate 0.07 % to 1.26 % Other than the effect on the derivative valuation recognized in operations, there was no accounting effect to the ratchet adjustments of certain convertible notes to reduce the conversion price to $ 0.05

Licensing Agreements

Licensing Agreements	12 Months Ended
	Dec. 31, 2021
Licensing Agreements
Licensing Agreements	Note 5 - Licensing Agreements Les Laboratories Servier As a result of the Asset Purchase Agreement that the Company entered into with Symplmed Pharmaceuticals LLC in June 2017, Symplmed assigned to the Company an Amended and Restated License and Commercialization Agreement with Les Laboratories Servier, pursuant to which the Company has the exclusive right to manufacture, have manufactured, develop, promote, market, distribute and sell Prestalia® in the U.S. (and its territories and possessions). On January 4, 2021, the licensor terminated the licensing agreement with the Company for the commercialization of Prestalia®. No Novosom Agreements In 2010, the Company entered into an asset purchase agreement with Novosom Verwaltungs GmbH (“Novosom”), pursuant to which the Company acquired intellectual property for Novosom’s SMARTICLES-based liposomal delivery system. In May 2018, the Company issued to Novosom 51,988 shares of our common stock, with a fair value of $ 75,000 , as additional consideration pursuant to the Asset Purchase Agreement. Such shares were due to Novosom as a result of the receipt by our company of a license fee under the License Agreement that we entered into with Lipomedics Inc. in February 2017. On December 23, 2019, Novosom repurchased the acquired intellectual property for $ 45,000 of which $ 20,000 was payable upon execution of the agreement and $ 25,000 was to be paid upon the Company’s achievement of certain performance obligations by June 30, 2020. The Company recognized $ 45,000 No License of DiLA 2 On March 16, 2018, the Company entered into an exclusive sublicensing agreement for certain intellectual property rights to its DiLA2 delivery system. The agreement included an upfront payment of $ 200,000

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Note 6 - Related Party Transactions Due to Related Party The Company and other related entities have had a commonality of ownership and/or management control, and as a result, the reported operating results and/or financial position of the Company could significantly differ from what would have been obtained if such entities were autonomous. The Company had a Master Services Agreement (“MSA”) with Autotelic Inc., a related party that is partly owned by one of the Company’s former Board members and executive officers, namely Vuong Trieu, Ph.D., effective November 15, 2016. The MSA stated that Autotelic Inc. would provide business functions and services to the Company and allowed Autotelic Inc. to charge the Company for these expenses paid on its behalf. Dr. Trieu resigned as a director of our company effective October 1, 2018. The Company and Autotelic Inc. agreed to terminate the MSA effective October 31, 2018. An unpaid balance for previous years services performed under the agreement of approximately $ 4,000 In addition, as of December 31, 2021, the Company owed various officers and directors approximately $ 42,000

Stockholders_ Equity

Stockholders’ Equity	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Stockholders’ Equity	Note 7 - Stockholders’ Equity Preferred Stock Adhera has authorized 100,000 shares of preferred stock for issuance and has designated 1,000 shares as Series B Preferred Stock (“Series B Preferred”) and 90,000 shares as Series A Junior Participating Preferred Stock (“Series A Preferred”). No shares of Series A Preferred or Series B Preferred are outstanding. In March 2014, Adhera designated 1,200 shares as Series C Convertible Preferred Stock (“Series C Preferred”). In August 2015, Adhera designated 220 shares as Series D Convertible Preferred Stock (“Series D Preferred”). In April 2018, Adhera designated 3,500 shares of Series E Convertible Preferred Stock (“Series E Preferred”). In July 2018, Adhera designated 2,200 shares of Series F Convertible Preferred Stock (“Series F Preferred”). In December 2019, Adhera designated 6,000 shares of Series G Convertible Preferred Stock (“Series G Preferred”). The Company plans to file a certificate of elimination with respect to the Series A and Series B stock and a certificate of decrease with respect to each of its Series C, D and F Preferred stock. As of December 31, 2021 the Company has not filed the certificate of elimination. Each subsequent authorization of Preferred Stock has liquidation preference over the previous Series. Series C Preferred Each share of Series C Preferred has a stated value of $ 5,000 5,100 voting rights of 666.67 votes per share 7.50 As of December 31, 2021, and December 31, 2020, 100 Series D Preferred Each share of Series D Preferred has a stated value of $ 5,000 300 voting rights of 1,250 votes per share 4.00 5 As of December 31, 2021, and December 31, 2020, 40 Series E Convertible Preferred Stock and Warrants The Series E Preferred Stock has a stated value of $ 5,000 per share and accrues 8 % dividends per annum that are payable in cash or stock at the Company’s discretion. The Series E Preferred has voting rights, dividend rights, liquidation preferences, conversion rights at the option of the holder and anti-dilution rights. Series E Preferred stock is convertible into shares of common stock at $ 0.50 . Anti-dilution price protection on Series E Preferred stock expired on February 10, 2020 . Warrants issued with Series E Convertible Preferred Stock have anti-dilution price protection, are exercisable for a period of five years, and contain customary exercise limitations. On March 19, 2021, the exercise price of the Series E warrants was adjusted from $ 0.50 0.05 25,900 518,000 390,000 0.16 262.27 .41 .43 As of May 17, 2021, the three-year anniversary of the closing of the Series E Preferred stock offering, all outstanding Series E Preferred stock may be converted by the Company into common stock upon written notification being provided by the Company to stockholders. As of December 31, 2021, the Company has not provided notice of conversion to the holders of the Series E Preferred stock. On June 8, 2021, an investor converted 8 10,000 101,010 53,571 75,000 On July 30, 2021, an investor converted 50 250,000 500,000 On October 4, 2021, the Company issued 255,540 shares of common stock upon the conversion of 20 shares Series E Preferred stock including accrued dividends of $ 27,770 On October 5, 2021, the Company issued 385,414 shares of common stock upon the conversion of 30 shares of Series E Preferred stock including accrued dividends of $ 42,707 On October 8, 2021, the Company issued 51,414 shares of common stock upon the conversion of 4 shares of Series E Preferred stock including accrued dividends of $ 5,707 On October 12, 2021, the Company issued 64,312 shares of common stock upon the conversion of 5 shares of Series E Preferred stock including accrued dividends of $ 7,156 On November 23, 2021, the Company issued 193,299 shares of common stock upon the conversion of 15 shares of Series E Preferred stock including accrued dividends of $ 21,649 As of December 31, 2021, the Company had a total of 30,405,600 warrants issued with Series E Preferred stock outstanding. The warrants expire in 2023 and have an exercise price of $ 0.05 The Company had accrued dividends on the Series E Preferred stock of approximately $ 5.0 3.7 At December 31, 2021 and December 31, 2020, there were 3,326 3,458 Series F Convertible Preferred Shares and Warrants The Series F Preferred Stock has a stated value of $ 5,000 per share and accrues 8 % dividends per annum that are payable in cash or stock at the Company’s discretion. The Series F Preferred has voting rights, dividend rights, liquidation preferences, conversion rights at the holders option and anti-dilution rights. Series F Preferred stock is convertible into shares of common stock at $ 0.50 . Anti-dilution price protection on Series F Preferred stock expired on February 10, 2020 . Warrants issued with Series F Convertible Preferred Stock have anti-dilution price protection, are exercisable for a period of five years, and contain customary exercise limitations. On October 30, 2019, the Company repurchased 20 shares of Series F Convertible Preferred Stock including accrued and unpaid dividends and warrants to purchase 150,000 shares of common stock for $ 100,000 from our former CEO pursuant to an amendment to the settlement agreement dated April 4, 2019. The Company also committed to purchase from such officer the remaining Series F Convertible Preferred Stock and related warrants held by such officer for $ 100,000 by not later than March 1, 2020. As of December 31, 2021, the Company had not repurchased the remaining shares. On March 19, 2021, the exercise price of the Series F warrants was adjusted from $ 0.50 0.05 25,900 518,000 31,000 0.16 262.27 .46 .53 On October 15, 2021, the Company issued 37,043 shares of common stock upon the conversion of 3 shares of Series F Preferred stock and including total accrued dividends of $ 3,521 As of November 9, 2021, the three-year anniversary of the closing of the Series F Preferred stock offering, all outstanding Series F Preferred stock may be converted by the Company into common stock upon written notification being provided by the Company to stockholders. As of December 31, 2021, the Company has not provided notice of conversion to the holders of the Series F Preferred stock. As of December 31, 2021, the Company had a total of 3,088,500 The Company had accrued dividends on the Series F Preferred stock of approximately $ 488,000 347,000 At December 31, 2021 and December 31, 2020, there were 358 361 Series G Convertible Preferred Shares The Series G Preferred Stock has a stated value of $ 5,000 8 0.50 As of December 31, 2021, no Common Stock On December 11, 2020, the Company issued 121,699 10 60,850 On December 21, 2020, the Company issued 121,480 10 60,740 On June 8, 2021, an investor converted 8 10,000 101,010 On June 8,2021, the Company issued 53,571 shares of common stock to the investor for a cashless exercise of 75,000 warrants. On July 30, 2021, and investor converted 50 250,000 500,000 On August 11, 2021, the Company issued 100,000 56,464 On August 18, 2021, the Company issued 100,000 62,220 On September 22, 2021, the Company issued 300,148 39,290 On October 4, 2021, the Company issued 255,540 20 27,770 On October 4, 2021, the Company issued 59,523 10,859 On October 5, 2021, the Company issued 385,414 30 42,707 On October 8, 2021, the Company issued 51,414 4 5,707 On October 8, 2021, the Company issued 59,523 12,233 On October 15, 2021, the Company issued 37,043 3 3,521 On November 4, 2021, the Company issued 153,227 250,000 On December 6, 2021, the Company issued 96,091 18,745 During the twelve-month period ending December 31, 2021, the company issued 3,366,012 million common shares upon the conversion of $ 98,141 principal and $ 70,160 of accrued interest on the February 2020 convertible note. The common shares issued upon conversions of the note for the period ended December 31, 2021 were valued at fair value based on the quoted trading prices on the conversion dates aggregating approximately $ 554,000 resulting in a loss on debt extinguishment of approximately $386,000 . Warrants As of December 31, 2021, there were 74,625,139 0.05 Schedule of Stockholders’ Equity Note, Warrants or Rights Warrant Summary: Shares 2023 2024 2025 2026 Issued with Series E Preferred Stock 30,405,600 30,405,600 — — — Issued with Series F Preferred Stock 3,088,500 3,088,500 — — — Issued with Convertible Notes 40,782,306 — 2,472,380 32,918,586 5,391,340 Other 348,733 10,080 335,452 3,201 — Total Warrants 74,625,139 33,504,180 2,807,832 32,921,787 5,391,340 The above includes 74,276,406 The intrinsic value of 74,625,139 warrants as of December 31, 2021 was $1,492,503. A total of 343,750 Series D warrants expired during the period ended December 31, 2021. In addition, there were 75,000 Series E warrants and 250,000 warrants issued with convertible notes exercised on a cashless basis for the twelve-month period ended December 31, 2021. As discussed in Note 2 above, the Company has issued convertible notes and warrants with variable conversion provisions. The conversion terms of the convertible notes are variable based on certain factors, such as the future price of the Company’s common stock and various default provisions related to the payment of the notes in Company stock. The number of shares of common stock to be issued under the convertible notes and warrants is based on the future price of the Company’s common stock. The number of shares of common stock issuable upon conversion of the promissory note is therefore, indeterminate. Due to the fact that the number of shares of common stock issuable exceed the Company’s authorized share limit as of December 31, 2021, the equity environment was tainted and all convertible debentures and warrants were included in the value of the derivative as of that date. Pursuant to ASC 815-15 Embedded Derivatives, the fair values of the warrants were recorded as derivative liabilities. On December 31, 2021, the Company evaluated all outstanding warrants to determine whether these instruments are tainted and, due to reasons discussed above, all warrants outstanding were considered tainted and were therefore, accounted for as derivative liabilities.

Stock Incentive Plans

Stock Incentive Plans	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Stock Incentive Plans	NOTE 8 - Stock Incentive Plans Stock Options The following table summarizes stock option activity for the year ended December 31, 2021 and 2020: Schedule of Share Based Payments Arrangement, Option Activity Options Outstanding Shares Weighted Average Exercise Price Outstanding, December 31, 2019 4,071,333 $ 0.58 Options expired / forfeited (3,679,983 ) $ 0.53 Outstanding, December 31, 2020 391,350 $ 1.00 Options expired / forfeited (7,300 ) $ 1.83 Outstanding, December 31, 2021 384,050 $ 0.97 Exercisable, December 31, 2021 384,050 $ 0.97 No stock options were granted during the years ended December 31, 2020 or 2021. The following table summarizes additional information on the Company’s stock options outstanding at December 31, 2021: Schedule of Share Based Payment Arrangement, Option, Exercise Price Range Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted- Average Remaining Contractual Life (Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $ 0.98 1.00 383,500 1.33 $ 0.98 383,500 $ 0.98 $ 1.70 4,050 0.02 $ 1.70 4,050 $ 1.70 Totals 384,050 1.32 $ 0.97 384,050 $ 0.97 No stock options were issued by the Company during the year ended December 31, 2021. As of December 31, 2021, the Company had no unrecognized compensation expense related to unvested stock options. Total expense related to stock options was zero 8,000 As of December 31, 2021, the intrinsic value of options outstanding or exercisable was zero there were no options outstanding with an exercise price less than $ 0.07

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 9 - Commitments and Contingencies Litigation Because of the nature of the Company’s business, it is subject to claims and/or threatened legal actions, which arise out of the normal course of business. As of the date of this filing, the Company is not aware of any pending lawsuits against it, its officers or directors. Leases The Company does not own or lease any real property or facilities that are material to its current business operations. If the Company continues its business operations, the Company may seek to lease facilities in order to support its operational and administrative needs. Share Repurchase Agreement On October 30, 2019, the Company repurchased 20 150,000 100,000 100,000 Licensing Agreement – MLR 1019 On July 28, 2021, the Company and Melior Pharmaceuticals II, LLC (“MP”) entered into an exclusive license agreement for the development, commercialization and exclusive license of MLR-1019. MLR-1019 is being developed as a new class of therapeutic for Parkinson’s disease (PD) and is, to the best of the Company’s knowledge, the only drug candidate today to address both movement and non-movement aspects of PD. Under the Agreement, the Company was granted an exclusive license to use the MP Patents and know-how to develop products in consideration for cash payments up to approximately $ 21.8 5 The license terminates upon the last expiration of the patents licensed by the Company, which is presently 2034 subject extensions and renewals of any of such patents. If the Company fails to have its common stock listed on Nasdaq or the NYSE (an “Uplisting Event”) within 12 months after the Company receives a Clinical Trial Authorization from the European Medicines Agency, then the Company’s commercial license and rights for using MP’s data shall terminate. Additionally, if the Company has completed the necessary steps to affect an Uplisting Event, the Company will have the option to purchase all rights held by MP on the MLR-1019 licensed products in consideration for 10 % of the outstanding shares of the Company’s common stock (immediately post Uplisting Event) and 2.5 % royalty of future gross product sales. As of December 31, 2021, no performance milestones had been met under the agreement. Licensing Agreement – MLR 1023 On August 24, 2021, the Company as licensee entered into an exclusive license agreement with Melior Pharmaceuticals I, Inc. for the development, commercialization and exclusive license of Melior’s MLR-1023. MLR-1023 is being developed as a novel therapeutic for Type 1 diabetes. Under the Agreement, the Company was granted an exclusive license to use the MP Patents and know-how to develop products in consideration for cash payments up to approximately $ 21.8 8 12 Under the original terms of the agreement if the Company failed to raise $4.0 million dollars within 120 days of the Effective Date then the License would immediately terminate unless, by 120 Days Adhera was in the process of completing transactions to complete the fundraising then an additional 30 Days would be provided to allow for the completion of the raise On November 17, 2021, Melior Pharmaceuticals I, Inc. extended the Company’s timeline from 120 days to 180 days from the effective of the agreement for the Company to raise $4.0 million dollars unless, by 180 Days Adhera is in the process of completing transactions to complete the fundraising then an additional 30 Days shall be provided to allow for the completion of required fundraising As of December 31, 2021, no performance milestones had been met under the agreement.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 10 - Income Taxes The Company has identified its federal and California and Louisiana state tax returns as “major” tax jurisdictions. The periods the Company’s income tax returns are subject to examination for these jurisdictions are 2018 through 2021 for federal and 2019 through 2021 for Louisiana. The Company believes its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that would result in a material change to our financial position. Therefore, no liabilities for uncertain income tax positions have been recorded. At December 31, 2021, the Company had available net operating loss carry-forwards for federal income tax reporting purposes of approximately $ 326 The Company’s net deferred tax assets, deferred tax liabilities and valuation allowance as of December 31, 2021 and 2020 are summarized as follows: Schedule of Deferred Tax Assets and Liabilities (in thousands) 2021 2020 Years Ended December 31, (in thousands) 2021 2020 Deferred tax assets: Net operating loss carryforwards $ 8,402 $ 7,741 Inventory reserve 114 Depreciation and amortization 1,272 2,226 Share based compensation 647 599 Other 613 297 Total deferred tax assets 10,935 10,977 Valuation allowance (10,935 ) (10,977 ) Net deferred tax assets — — Deferred tax liabilities: Intangible assets — — Net deferred tax liabilities $ — $ — The Company records a valuation allowance in the full amount of our net deferred tax assets since realization of such tax benefits has been determined by our management to be less likely than not. The valuation allowance decreased $ 42,000 0.6 As of the date of this filing, the Company has not filed its 2021 federal and state corporate income tax returns. The Company expects to file the 2021 return by the extension filing date.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	NOTE 11 - Subsequent Events Default on Convertible Notes On January 2, 2022, the company defaulted on certain covenants contained in the October 4, 2021, convertible note and the interest rate reset to 16% On January 5, 2022, the company defaulted on certain covenants contained in the October 7, 2021, convertible note and the interest rate reset to 16% Conversion of Principal and Interest on Convertible Note On January 27, 2022, the holder of the June 25, 2021, convertible note converted $ 9,500 421 0.039 254,401 Amendment to Licensing Agreement On February 16, 2022, an addendum to the licensing agreement dated August 4, 2021, was executed by the Company and Melior Pharmaceuticals I, Inc, extending the requirement by the Company to raise $4.0 million dollars to June 16, 2022 Issuance of Convertible Promissory Note On March 15, 2022, the Company entered into a Securities Purchase Agreement (“SPA”) with an institutional investor pursuant to which the Company issued the Buyer a 10% Convertible Note in the principal amount of $ 250,000 for a purchase price of $ 200,000 reflecting a $ 50,000 original issue discount . The Company received total consideration of $ 180,000 after debt issuance costs of $ 20,000 . In addition, the Company issued 50,000 shares of common stock as a commitment fee to the investor. The company will record a debt discount related to the original issue discount and will evaluate the note terms for derivative accounting treatment. The Note provides for guaranteed interest at the rate of 10% per annum for the 12 months from and after the original issue date of the Note for an aggregate guaranteed interest of $ 25,000 , all of which guaranteed interest shall be deemed earned as of the date of the note. The principal amount and the guaranteed interest shall be due and payable in seven equal monthly payments each, $ 39,285.71 , commencing on August 15, 2022, and continuing on the 15th day of each month until paid in full not later than March 15, 2023, the maturity date. The Note is convertible into shares of common stock at any time following any event of default at the Buyer’s option at a conversion price of ninety percent (90%) per share of the lowest per-share trading price of the Company; stock during the ten trading day periods before the conversion, subject to certain adjustments.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Adhera Therapeutics, Inc. and the wholly-owned subsidiaries, Ithena, Cequent, MDRNA, and Atossa, and eliminate any inter-company balances and transactions. All wholly-owned subsidiaries of Adhera Therapeutics, Inc. are inactive.
Going Concern and Management’s Liquidity Plans	Going Concern and Management’s Liquidity Plans The accompanying consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. As of December 31, 2021, the Company had cash and cash equivalents of approximately $ 76,000 25.1 The Company has incurred recurring losses and negative cash flows from operations since inception and has funded its operating losses through the sale of common stock, preferred stock, warrants to purchase common stock, convertible notes and secured promissory notes. The Company incurred a net loss of approximately $ 6.4 million for the year ended December 31, 2021 and used cash in operating activities of approximately $ 665,000 53.0 million as of December 31, 2021. In addition, to the extent that the Company continues its business operations, the Company anticipates that it will continue to have negative cash flows from operations, at least into the near future. However, the Company cannot be certain that it will be able to obtain such funds required for its our operations at terms acceptable to the Company or at all. General market conditions, as well as market conditions for companies in the Company’s financial and business position, as well as the ongoing issue arising from the COVID-19 pandemic, may make it difficult for the Company to seek financing from the capital markets, and the terms of any financing may adversely affect the holdings or the rights of its stockholders. If the Company is unable to obtain additional financing in the future, there may be a negative impact on the financial viability of the Company. The Company plans to increase working capital by managing its cash flows and expenses, divesting development assets and raising additional capital through private or public equity or debt financing. There can be no assurance that such financing or partnerships will be available on terms which are favorable to the Company or at all. While management of the Company believes that it has a plan to fund ongoing operations, there is no assurance that its plan will be successfully implemented. Failure to raise additional capital through one or more financings, divesting development assets or reducing discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this Report. The consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties. Summary of Significant Accounting Policies
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. As of December 31, 2021, the Company had approximately $ 76,000 in cash equivalents. The Company deposits its cash with major financial institutions and may at times exceed the federally insured limit. At December 31, 2021, the Company’s cash balance did not exceed the federal insurance limit.
Use of Estimates	Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include accruals related to our operating activity including legal and other consulting expenses, the fair value of non-cash equity-based issuances, the fair value of derivative liabilities, and the valuation allowance on deferred tax assets. Actual results could differ materially from such estimates under different assumptions or circumstances.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company considers the fair value of cash, accounts payable, debt, and accrued expenses not to be materially different from their carrying value. These financial instruments have short-term maturities. We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. As of December 31, 2021, the Company measured conversion features on outstanding convertible notes and warrants as a derivative liability using significant unobservable prices that are based on little or no verifiable market data, which is Level 3 in the fair value hierarchy, resulting in a fair value estimate of approximately $ 7.7 million. The value of the derivative liability as of December 31, 2021, was determined by using the binomial lattice model using the following inputs: 0.069 % to 1.26 % risk free rate, volatility of 255 % to 399 % and time to maturity of 0 - 0.60 years. There were no liabilities or assets measured at fair value on a non-recurring basis as of December 31, 2021, and there were no liabilities or assets measured at fair value on a recurring or non-recurring basis as of December 31, 2020. Schedule of Fair Value Measurements (in thousands) (Level 1) (Level 2) (Level 3) Total Fair Value Measurements at December 31, 2021 Quoted Prices in Active Markets for Identical Assets Other Observable Inputs Significant Unobservable Inputs (in thousands) (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 7,697 $ 7,697 Total $ - $ - $ 7,697 $ 7,697 A roll forward of the level 3 valuation financial instruments is as follows: Schedule of Roll Forward of Level 3 Financial Instruments Year Ended December 31, 2021 (In thousands) Warrants Notes Total Balance at December 31, 2020 $ — $ — $ — Initial valuation of derivative liabilities included in debt discount — 377 377 Initial valuation of derivative liabilities included in derivative expense 246 1,348 1,594 Reclassification of derivative liabilities gain to loss on debt extinguishment (52 ) (193 ) (245 ) Reclass from additional paid-in capital 3,107 355 3,462 Change in fair value included in derivative expense 2,035 474 2,509 Balance at December 31, 2021 $ 5,336 $ 2,361 $ 7,697 ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding equity instruments.
Convertible Debt and Warrant Accounting	Convertible Debt and Warrant Accounting Debt with warrants In accordance with ASC Topic 470-20-25, when the Company issues debt with warrants, the Company treats the relative fair value of the warrants as a debt discount, recorded as a contra-liability against the debt, and amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations. The offset to the contra-liability is recorded as additional paid in capital in the Company’s consolidated balance sheets if the warrants are not treated as a derivative. The Company determines the fair value of the warrants using the Black-Scholes Option Pricing Model (“Black-Scholes”), the binomial model or the Monte Carlo Method based upon the underlying conversion features of the debt and then computes and records the relative fair value as a debt discount. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations. Convertible debt – derivative treatment When the Company issues debt with a conversion feature, it first assesses whether the conversion feature meets the requirements to be accounted for as stock settled debt. If it does not meet those requirements then it is assessed on whether the conversion feature should be bifurcated and treated as a derivative liability, as follows: a) one or more underlyings, typically the price of our common stock; b) one or more notional amounts or payment provisions or both, generally the number of shares upon conversion; c) no initial net investment, which typically excludes the amount borrowed; and d) net settlement provisions, which in the case of convertible debt generally means the stock received upon conversion can be readily sold for cash. An embedded equity-linked component that meets the definition of a derivative does not have to be separated from the host instrument if the component qualifies for the scope exception for certain contracts involving an issuer’s own equity. The scope exception applies if the contract is both a) indexed to its own stock; and b) classified in stockholders’ equity in its statement of financial position. Convertible debt – beneficial conversion feature Prior to the Company’s adoption of ASU No. 2020-06, Debt—Debt with Conversion and Other Options Derivatives and Hedging—Contracts in Entity’s Own Equity Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity If the conversion feature does not qualify for either the derivative treatment or as a BCF, the convertible debt is treated as traditional debt.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements Recently Adopted In January 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-04, Intangibles-Goodwill and Other (Topic 350) (“ASU 2017-04”), which will simplify the goodwill impairment calculation by eliminating Step 2 from the current goodwill impairment test. The new standard does not change how a goodwill impairment is identified. The Company will continue to perform its quantitative goodwill impairment test by comparing the fair value of its reporting unit to its carrying amount, but if the Company is required to recognize a goodwill impairment charge, under the new standard, the amount of the charge will be calculated by subtracting the reporting unit’s fair value from its carrying amount. Under the current standard, if the Company is required to recognize a goodwill impairment charge, Step 2 requires it to calculate the implied value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination and the amount of the charge is calculated by subtracting the reporting unit’s implied fair value of goodwill from the goodwill carrying amount. The standard was effective January 1, 2020. The adoption of ASU 2017-04 did not have a material impact on the Company’s historical consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which will simplify the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts on an entity’s own equity. Specifically, the new standard will remove the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It will also remove certain settlement conditions that are currently required for equity contracts to qualify for the derivative scope exception and will simplify the diluted earnings per share calculation for convertible instruments. ASU 2020-06 will be effective January 1, 2022, for the Company and may be applied using a full or modified retrospective approach. Early adoption is permitted, but no earlier than January 1, 2021, for the Company. The Company adopted ASU No. 2020-06 on January 1, 2021. Management determined such adoption did not have a material impact on the overall stockholders’ equity (deficit) in the Company’s consolidated financial statements. Not Yet Adopted In May 2021, FASB issued ASU 2021-04: Earnings Per Share (Topic 260), Debt— Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40), to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in ASU 2021-04 provide the following guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic: 1. An entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as an exchange of the original instrument for a new instrument. 2. An entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as follows: a. For a modification or an exchange that is a part of or directly related to a modification or an exchange of an existing debt instrument or line-of-credit or revolving-debt arrangements (hereinafter, referred to as a “debt” or “debt instrument”), as the difference between the fair value of the modified or exchanged written call option and the fair value of that written call option immediately before it is modified or exchanged. Specifically, an entity should consider: i. An increase or a decrease in the fair value of the modified or exchanged written call option in applying the 10 percent cash flow test and/or calculating the fees between debtor and creditor in accordance with Subtopic 470-50, Debt—Modifications and Extinguishments. ii. An increase (but not a decrease) in the fair value of the modified or exchanged written call option in calculating the third-party costs in accordance with Subtopic 470-50. b. For all other modifications or exchanges, as the excess, if any, of the fair value of the modified or exchanged written call option over the fair value of that written call option immediately before it is modified or exchanged. 3. An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange on the basis of the substance of the transaction, in the same manner as if cash had been paid as consideration, as follows: a. A financing transaction to raise equity. The effect should be recognized as an equity issuance cost in accordance with the guidance in Topic 340, Other Assets and Deferred Costs. b. A financing transaction to raise or modify debt. The effect should be recognized as a cost in accordance with the guidance in Topic 470, Debt, and Topic 835, Interest. c. Other modifications or exchanges that are not related to financings or compensation for goods or services or other exchange transactions within the scope of another Topic. The effect should be recognized as a dividend. For entities that present EPS in accordance with Topic 260, that dividend should be an adjustment to net income (or net loss) in the basic EPS calculation. An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option to compensate for goods or services in accordance with the guidance in Topic 718, Compensation—Stock Compensation. In a multiple-element transaction (for example, one that includes both debt financing and equity financing), the total effect of the modification should be allocated to the respective elements in the transaction. The amendments in ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt the amendments in ASU 2021-04 in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company is evaluating the impact of the revised guidance and believes that it will not have a significant impact on its financial statements. Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.
Net Loss per Common Share	Net Loss per Common Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. Potentially dilutive securities which include outstanding warrants, stock options, convertible notes and preferred stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. For all periods presented, basic and diluted net loss were the same. The following table presents the computation of net loss per share (in thousands, except share and per share data): Schedule of Earnings Per Share, Basic and Diluted (in thousands except share and per share data) 2021 2020 December 31, (in thousands except share and per share data) 2021 2020 Numerator Net loss $ (6,351 ) $ (3,766 ) Preferred stock dividends (2,054 ) (1,540 ) Net Loss allocable to common stockholders $ (8,405 ) $ (5,306 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 13,003,658 10,876,513 Net loss per share of common stock, basic and diluted Net loss per share, basic and diluted $ (0.65 ) $ (0.49 ) The following number of shares have been excluded from diluted net (loss) since such inclusion would be anti-dilutive: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share 2021 2020 Year Ended December 31, 2021 2020 Stock options outstanding 384,050 391,350 Convertible notes 48,696,732 33,658,590 Warrants 74,625,139 78,181,855 Series C Preferred Stock 66,667 66,667 Series D Preferred Stock 50,000 50,000 Series E Preferred Stock 43,240,749 42,055,232 Series F Preferred Stock 4,555,010 4,303,767 Total 171,618,347 158,707,461 As of December 31, 2021, the Company’s fully diluted common stock equivalents exceeded the 180,000,000
Stock-Based Compensation	Stock-Based Compensation The Company applies the provisions of ASC 718, Compensation—Stock Compensation (“ASC 718”) For stock options issued, the Company estimates the grant date fair value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised if and when a forfeiture becomes probable.
Income Taxes	Income Taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss and credit carry forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of Fair Value Measurements	Schedule of Fair Value Measurements (in thousands) (Level 1) (Level 2) (Level 3) Total Fair Value Measurements at December 31, 2021 Quoted Prices in Active Markets for Identical Assets Other Observable Inputs Significant Unobservable Inputs (in thousands) (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 7,697 $ 7,697 Total $ - $ - $ 7,697 $ 7,697
Schedule of Roll Forward of Level 3 Financial Instruments	A roll forward of the level 3 valuation financial instruments is as follows: Schedule of Roll Forward of Level 3 Financial Instruments Year Ended December 31, 2021 (In thousands) Warrants Notes Total Balance at December 31, 2020 $ — $ — $ — Initial valuation of derivative liabilities included in debt discount — 377 377 Initial valuation of derivative liabilities included in derivative expense 246 1,348 1,594 Reclassification of derivative liabilities gain to loss on debt extinguishment (52 ) (193 ) (245 ) Reclass from additional paid-in capital 3,107 355 3,462 Change in fair value included in derivative expense 2,035 474 2,509 Balance at December 31, 2021 $ 5,336 $ 2,361 $ 7,697
Schedule of Earnings Per Share, Basic and Diluted	The following table presents the computation of net loss per share (in thousands, except share and per share data): Schedule of Earnings Per Share, Basic and Diluted (in thousands except share and per share data) 2021 2020 December 31, (in thousands except share and per share data) 2021 2020 Numerator Net loss $ (6,351 ) $ (3,766 ) Preferred stock dividends (2,054 ) (1,540 ) Net Loss allocable to common stockholders $ (8,405 ) $ (5,306 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 13,003,658 10,876,513 Net loss per share of common stock, basic and diluted Net loss per share, basic and diluted $ (0.65 ) $ (0.49 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following number of shares have been excluded from diluted net (loss) since such inclusion would be anti-dilutive: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share 2021 2020 Year Ended December 31, 2021 2020 Stock options outstanding 384,050 391,350 Convertible notes 48,696,732 33,658,590 Warrants 74,625,139 78,181,855 Series C Preferred Stock 66,667 66,667 Series D Preferred Stock 50,000 50,000 Series E Preferred Stock 43,240,749 42,055,232 Series F Preferred Stock 4,555,010 4,303,767 Total 171,618,347 158,707,461

Notes Payable and Convertible_2

Notes Payable and Convertible Promissory Notes (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Schedule of Convertible Promissory Notes	The following table summarizes the Company’s outstanding convertible notes as of December 31, 2021, and December 31, 2020: Schedule of Convertible Promissory Notes (in thousands) December 31, 2021 December 31, 2020 Convertible Notes $ 1,516 $ 720 Unamortized discounts (530 ) (79 ) Convertible Notes Payable $ 986 $ 641
Schedule of Fair Value of Derivative Liabilities Estimated Issuance and Valuation Mode	During the year ended December 31, 2021, the fair value of the derivative liabilities was estimated at issuance and at the December 31, 2021, using the Binomial Lattice valuation model with the following assumptions: Schedule of Fair Value of Derivative Liabilities Estimated Issuance and Valuation Mode Dividend rate — % Term (in years) 0.01 to 1 year Volatility 247 % to 412 % Risk-free interest rate 0.07 % to 1.26 %

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Schedule of Stockholders’ Equity Note, Warrants or Rights	Schedule of Stockholders’ Equity Note, Warrants or Rights Warrant Summary: Shares 2023 2024 2025 2026 Issued with Series E Preferred Stock 30,405,600 30,405,600 — — — Issued with Series F Preferred Stock 3,088,500 3,088,500 — — — Issued with Convertible Notes 40,782,306 — 2,472,380 32,918,586 5,391,340 Other 348,733 10,080 335,452 3,201 — Total Warrants 74,625,139 33,504,180 2,807,832 32,921,787 5,391,340

Stock Incentive Plans (Tables)

Stock Incentive Plans (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Schedule of Share Based Payments Arrangement, Option Activity	The following table summarizes stock option activity for the year ended December 31, 2021 and 2020: Schedule of Share Based Payments Arrangement, Option Activity Options Outstanding Shares Weighted Average Exercise Price Outstanding, December 31, 2019 4,071,333 $ 0.58 Options expired / forfeited (3,679,983 ) $ 0.53 Outstanding, December 31, 2020 391,350 $ 1.00 Options expired / forfeited (7,300 ) $ 1.83 Outstanding, December 31, 2021 384,050 $ 0.97 Exercisable, December 31, 2021 384,050 $ 0.97
Schedule of Share Based Payment Arrangement, Option, Exercise Price Range	The following table summarizes additional information on the Company’s stock options outstanding at December 31, 2021: Schedule of Share Based Payment Arrangement, Option, Exercise Price Range Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted- Average Remaining Contractual Life (Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $ 0.98 1.00 383,500 1.33 $ 0.98 383,500 $ 0.98 $ 1.70 4,050 0.02 $ 1.70 4,050 $ 1.70 Totals 384,050 1.32 $ 0.97 384,050 $ 0.97

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities	The Company’s net deferred tax assets, deferred tax liabilities and valuation allowance as of December 31, 2021 and 2020 are summarized as follows: Schedule of Deferred Tax Assets and Liabilities (in thousands) 2021 2020 Years Ended December 31, (in thousands) 2021 2020 Deferred tax assets: Net operating loss carryforwards $ 8,402 $ 7,741 Inventory reserve 114 Depreciation and amortization 1,272 2,226 Share based compensation 647 599 Other 613 297 Total deferred tax assets 10,935 10,977 Valuation allowance (10,935 ) (10,977 ) Net deferred tax assets — — Deferred tax liabilities: Intangible assets — — Net deferred tax liabilities $ — $ —

Schedule of Fair Value Measurem

Schedule of Fair Value Measurements (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Derivative liability	$ 7,697
Total	7,697
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Derivative liability
Total
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Derivative liability
Total
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Derivative liability	7,697
Total	$ 7,697

Schedule of Roll Forward of Lev

Schedule of Roll Forward of Level 3 Financial Instruments (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)
Short-term Debt [Line Items]
Balance at December 31, 2020
Initial valuation of derivative liabilities included in debt discount	377
Initial valuation of derivative liabilities included in derivative expense	1,594
Reclassification of derivative liabilities gain to loss on debt extinguishment	(245)
Reclass from additional paid-in capital	3,462
Change in fair value included in derivative expense	2,509
Balance at December 31, 2021	7,697
Warrants [Member]
Short-term Debt [Line Items]
Balance at December 31, 2020
Initial valuation of derivative liabilities included in debt discount
Initial valuation of derivative liabilities included in derivative expense	246
Reclassification of derivative liabilities gain to loss on debt extinguishment	(52)
Reclass from additional paid-in capital	3,107
Change in fair value included in derivative expense	2,035
Balance at December 31, 2021	5,336
Convertible Notes [Member]
Short-term Debt [Line Items]
Balance at December 31, 2020
Initial valuation of derivative liabilities included in debt discount	377
Initial valuation of derivative liabilities included in derivative expense	1,348
Reclassification of derivative liabilities gain to loss on debt extinguishment	(193)
Reclass from additional paid-in capital	355
Change in fair value included in derivative expense	474
Balance at December 31, 2021	$ 2,361

Schedule of Earnings Per Share,

Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Net loss	$ (6,351)	$ (3,766)
Preferred stock dividends	(2,054)	(1,540)
Net Loss allocable to common stockholders	$ (8,405)	$ (5,306)
Weighted average common shares outstanding used to compute net loss per share, basic and diluted	13,003,658	10,876,513
Net loss per share, basic and diluted	$ (0.65)	$ (0.49)

Schedule of Antidilutive Securi

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	171,618,347	158,707,461
Stock Options Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	384,050	391,350
Convertible Notes Payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	48,696,732	33,658,590
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	74,625,139	78,181,855
Series C Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	66,667	66,667
Series D Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	50,000	50,000
Series E Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	43,240,749	42,055,232
Series F Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	4,555,010	4,303,767

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Cash and cash equivalents	$ 76,000
Working capital	25,100,000
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	6,400,000
Net Cash Used in Operating Activities	665,000	$ 588,000
Retained earnings accumulated deficit	53,000,000
Cash Equivalents, at Carrying Value	76,000
Fair Value, Net Asset (Liability)	$ 0	$ 0
Common stock, shares authorized	180,000,000	180,000,000
Minimum [Member]
Property, Plant and Equipment [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	0.069%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate	255.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	0 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.26%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate	399.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	7 months 6 days
Fair Value, Inputs, Level 3 [Member]
Property, Plant and Equipment [Line Items]
Long-term Debt, Fair Value	$ 7,700,000

Prepaid Expenses (Details Narra

Prepaid Expenses (Details Narrative) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Prepaid Expenses
Prepaid expesnes	$ 120,000	$ 0

Schedule of Convertible Promiss

Schedule of Convertible Promissory Notes (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
Convertible Notes	$ 1,516	$ 720
Unamortized discounts	(530)	(79)
Convertible Notes Payable	$ 986	$ 641

Schedule of Fair Value of Deriv

Schedule of Fair Value of Derivative Liabilities Estimated Issuance and Valuation Mode (Details)	Dec. 31, 2021
Measurement Input, Expected Dividend Rate [Member]
Debt Instrument [Line Items]
Risk-free interest rate	0
Measurement Input, Expected Term [Member] | Minimum [Member]
Debt Instrument [Line Items]
Term (in years)	3 days
Measurement Input, Expected Term [Member] | Maximum [Member]
Debt Instrument [Line Items]
Term (in years)	1 year
Measurement Input, Price Volatility [Member] | Minimum [Member]
Debt Instrument [Line Items]
Risk-free interest rate	247
Measurement Input, Price Volatility [Member] | Maximum [Member]
Debt Instrument [Line Items]
Risk-free interest rate	412
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Debt Instrument [Line Items]
Risk-free interest rate	0.07
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Debt Instrument [Line Items]
Risk-free interest rate	1.26

Notes Payable and Convertible_3

Notes Payable and Convertible Promissory Notes (Details Narrative)	Nov. 29, 2021USD ($)shares	Nov. 15, 2021$ / sharesshares	Nov. 04, 2021shares	Oct. 27, 2021	Oct. 12, 2021	Oct. 07, 2021USD ($)$ / sharesshares	Oct. 04, 2021USD ($)$ / sharesshares	Sep. 13, 2021USD ($)shares	Aug. 17, 2021USD ($)$ / sharesshares	Aug. 16, 2021USD ($)shares	Aug. 11, 2021USD ($)$ / sharesshares	Jul. 31, 2021	Jul. 29, 2021USD ($)shares	Jun. 25, 2021USD ($)$ / sharesshares	Apr. 12, 2021USD ($)$ / sharesshares	Mar. 19, 2021USD ($)$ / sharesshares	Jan. 31, 2021USD ($)$ / sharesshares	Oct. 30, 2020USD ($)$ / sharesshares	Aug. 05, 2020	Jun. 26, 2020USD ($)$ / shares	May 05, 2020$ / shares	Feb. 05, 2020USD ($)	Dec. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Nov. 30, 2021$ / sharesshares	Nov. 09, 2021	Apr. 30, 2021	Jun. 15, 2020	Aug. 05, 2019USD ($)
Short-term Debt [Line Items]
Debt instrument, interest rate																											24.00%
Accrued interest																							$ 2,000,000
Convertible Notes Payable, Current																							986,000	$ 641,000
Debt instrument, convertible, conversion price | $ / shares																										$ 0.05
Debt discount to be amortized																							530,000	79,000
Debt discount																							398,000	839,000
Debt conversion amount																							554,000
Loss on extinguishment of debt																							386,000
Loss on fair value of derivative liabilities																							(4,103,000)
Conversion of convertible debt																							554,000
Convertible, Beneficial Conversion Feature																								95,000
Warrants to purchase common stock | shares			250,000																							131,667
Class of warrant or right, exercise price of warrants or rights | $ / shares														$ 0.08									$ 0.05			$ 0.05
Shares issued for warrants exercise | shares			153,227
Reclassification of additional paid in capital to derivative liability																							$ 3,462,000
Senior Secured Convertible Promissory Note [Member]
Short-term Debt [Line Items]
Interest expense																							17,000
Senior Secured Convertible Promissory Note One [Member]
Short-term Debt [Line Items]
Principal amount																		$ 111,111					$ 111,111
Debt Issuance Costs, Net																		$ 9,000
Debt instrument, interest rate																		10.00%					125.00%
Interest expense																								2,000
Amortization of Debt Issuance Costs																								1,300
Accured interest																							$ 19,000
Debt Instrument, Interest Rate, Effective Percentage																		10.00%										18.00%
Debt instrument, convertible, conversion price | $ / shares																$ 0.05		$ 0.07
Warrants and Rights Outstanding, Term																11 months 1 day
Debt discount																							$ 79,000	41,300
Premimum Description																							The 25% premium will be recorded once a demand occurs
Proceeds from issuance of secured debt																		$ 100,000
Convertible, Beneficial Conversion Feature																		45,000
Beneficial Conversion Feature																		$ 69,000
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger																		70.00%
Warrants to purchase common stock | shares																952,379		1,587,301
Deemed dividend																$ 57,000
Senior Secured Convertible Promissory Note One [Member] | Valuation Technique, Option Pricing Model [Member]
Short-term Debt [Line Items]
Debt discount to be amortized																		$ 6,000
Unamortized Debt Issuance Expense																		5,000
Senior Secured Convertible Promissory Note One [Member] | Measurement Input, Risk Free Interest Rate [Member]
Short-term Debt [Line Items]
Warrants and Rights Outstanding, Measurement Input																0.16
Senior Secured Convertible Promissory Note One [Member] | Measurement Input, Price Volatility [Member]
Short-term Debt [Line Items]
Warrants and Rights Outstanding, Measurement Input																262.27
Senior Secured Convertible Promissory Note - January 2021 [Member]
Short-term Debt [Line Items]
Principal amount																	$ 52,778
Debt Issuance Costs, Net																	2,000
Interest expense																							$ 6,700
Accured interest																							$ 6,700
Convertible Notes Payable, Current																	$ 47,500
Debt Instrument, Interest Rate, Effective Percentage																	10.00%						125.00%
Debt instrument, convertible, conversion price | $ / shares																$ 0.05	$ 0.07
Warrants and Rights Outstanding, Term																11 months 19 days
Debt discount to be amortized																	$ 2,000
Debt discount																							$ 35,000
Premimum Description																							The 25% premium will be recorded once a demand occurs
Debt default interest rate												18.00%
Deemed dividend																$ 27,000
Conversion Ratio																	0.70
Warrants issued | shares																452,372	753,968
Class of warrant or right, exercise price of warrants or rights | $ / shares																	$ 0.08
FairValueMethod																	$ 1,000
Debt instrument, unamortized discount, current																	35,000
Notes Payable																							$ 52,778
Senior Secured Convertible Promissory Note - January 2021 [Member] | Investor and lender [Member]
Short-term Debt [Line Items]
Debt discount to be amortized																	5,278
Senior Secured Convertible Promissory Note - January 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Short-term Debt [Line Items]
Warrants and Rights Outstanding, Measurement Input																0.16
Senior Secured Convertible Promissory Note - January 2021 [Member] | Measurement Input, Price Volatility [Member]
Short-term Debt [Line Items]
Warrants and Rights Outstanding, Measurement Input																262.27
Senior Secured Convertible Promissory Note April 2021 [Member]
Short-term Debt [Line Items]
Principal amount															$ 66,667								$ 66,667
Debt instrument, interest rate															10.00%								125.00%
Debt maturity date															Oct. 12, 2021
Interest expense																							$ 6,100
Accured interest																							6,100
Convertible Notes Payable, Current															$ 60,000
Debt Instrument, Interest Rate, Effective Percentage															10.00%
Debt instrument, convertible, conversion price | $ / shares															$ 0.075
Debt Conversion, Converted Instrument, Rate															70.00%
Debt discount to be amortized															$ 34,000
Debt discount															3,000
Premimum Description					The 25% premium will be recorded once a demand occurs
Debt default interest rate					18.00%
Debt instrument, unamortized discount, current															$ 6,667								37,500
Senior Secured Convertible Promissory Note April 2021 [Member] | Investor [Member]
Short-term Debt [Line Items]
Warrants and Rights Outstanding, Term															5 years
Warrants to purchase common stock | shares															800,000
Class of warrant or right, exercise price of warrants or rights | $ / shares															$ 0.095
Senior Secured Convertible Promissory Note - June 2021 [Member]
Short-term Debt [Line Items]
Principal amount														$ 66,500									66,500
Debt instrument, interest rate														10.00%
Debt maturity date														Jun. 25, 2022
Accured interest																							5,700
Debt Instrument, Interest Rate, Effective Percentage														5.00%
Debt instrument, convertible, conversion price | $ / shares														$ 0.075
Debt Conversion, Converted Instrument, Rate														65.00%
Warrants and Rights Outstanding, Term														3 years
Debt discount to be amortized														$ 5,040									38,700
Debt discount														15,784
Proceeds from issuance of secured debt														$ 63,000
Warrants to purchase common stock | shares														800,000
Unamortized Debt Issuance Expense														$ 9,300
Class of warrant or right, exercise price of warrants or rights | $ / shares														$ 0.095
Debt instrument, unamortized discount, current														$ 3,500
Considerations														$ 76,000
Stock Issued During Period, Shares, New Issues | shares														47,547
Derivative liabilities														$ 102,823
Derivative expense														87,039
Debt discount														$ 66,500
Secured Convertible Promissory Note - August 11, 2021 [Member]
Short-term Debt [Line Items]
Principal amount											$ 220,500												220,500
Debt Issuance Costs, Net											$ 30,000
Debt instrument, interest rate											10.00%
Interest expense																							15,800
Accured interest																							15,800
Debt instrument, convertible, conversion price | $ / shares											$ 0.075															$ 0.05
Debt Conversion, Converted Instrument, Rate											65.00%
Debt discount to be amortized											$ 220,500												134,100
Debt discount											$ 106,505												86,400
Warrants to purchase common stock | shares											800,000															720,000
Class of warrant or right, exercise price of warrants or rights | $ / shares																										$ 0.05
Debt instrument, unamortized discount, current											$ 10,500
Considerations											$ 210,000
Stock Issued During Period, Shares, New Issues | shares											140,000
Derivative liabilities											$ 340,893
Derivative expense											$ 234,388
Debt term											1 year
Secured Convertible Promissory Note - August 17, 2021 [Member]
Short-term Debt [Line Items]
Principal amount									$ 220,500														220,500
Debt Issuance Costs, Net											$ 30,000
Debt instrument, interest rate									10.00%
Debt maturity date				Feb. 17, 2023
Interest expense																							15,400
Accured interest																							15,400
Debt instrument, convertible, conversion price | $ / shares									$ 0.075
Debt Conversion, Converted Instrument, Rate									65.00%
Debt discount to be amortized											220,500												157,900
Debt discount											100,571												62,600
Warrants to purchase common stock | shares									800,000
Debt instrument, unamortized discount, current									$ 10,500		10,500
Considerations									$ 210,000
Derivative liabilities											398,404
Derivative expense											$ 297,833
Secured Convertible Promissory Note - August 17, 2021 [Member] | Minimum [Member]
Short-term Debt [Line Items]
Debt instrument, convertible, conversion price | $ / shares									$ 0.08
Secured Convertible Promissory Note Two [Member]
Short-term Debt [Line Items]
Debt term									1 year
Secured Convertible Promissory Note - October 4, 2021 [Member]
Short-term Debt [Line Items]
Principal amount							$ 131,250																131,250
Debt Issuance Costs, Net							$ 15,000
Debt instrument, interest rate							10.00%
Amortization of Debt Issuance Costs																							32,000
Accured interest																							3,200
Debt instrument, convertible, conversion price | $ / shares							$ 0.075
Debt discount to be amortized							$ 131,250																99,200
Debt discount							$ 77,891
Commitment fee | shares							43,459
Warrants to purchase common stock | shares							476,190
Debt instrument, unamortized discount, current							$ 6,250
Considerations							110,000
Derivative liabilities							564,943
Derivative expense							$ 487,052
Convertible redeemable percentage							10.00%
Aggregate exercise price							$ 45,238
Interest Expense																							3,200
Secured Convertible Promissory Note October 7, 2021 [Member]
Short-term Debt [Line Items]
Principal amount						$ 131,250																	131,250
Debt Issuance Costs, Net						$ 15,000
Debt instrument, interest rate						10.00%
Interest expense																							3,100
Accured interest																							3,100
Debt instrument, convertible, conversion price | $ / shares						$ 0.075
Debt discount to be amortized									$ 131,250														100,300
Debt discount						$ 76,517																	30,900
Warrants to purchase common stock | shares						476,190
Debt instrument, unamortized discount, current									6,250
Considerations						$ 110,000
Derivative liabilities						564,184
Derivative expense						487,667
Aggreggate exercise price						$ 45,238
Warrant [Member] | Senior Secured Convertible Promissory Note One [Member]
Short-term Debt [Line Items]
Debt discount to be amortized																		66,000
Warrant [Member] | Senior Secured Convertible Promissory Note - January 2021 [Member]
Short-term Debt [Line Items]
Debt Issuance Costs, Net																	$ 1,000
Warrants and Rights Outstanding, Term																	1 year
Debt discount to be amortized																	$ 32,000
Debt discount																	$ 3,000
Warrant [Member] | Senior Secured Convertible Promissory Note - January 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Short-term Debt [Line Items]
Warrants and Rights Outstanding, Measurement Input																	0.45
Warrant [Member] | Senior Secured Convertible Promissory Note - January 2021 [Member] | Measurement Input, Price Volatility [Member]
Short-term Debt [Line Items]
Warrants and Rights Outstanding, Measurement Input																	240.83
Warrant [Member] | Senior Secured Convertible Promissory Note April 2021 [Member]
Short-term Debt [Line Items]
Debt instrument, convertible, conversion price | $ / shares														$ 0.075
Warrants and Rights Outstanding, Term														11 months 15 days	1 year
Debt discount															$ 3,700
Deemed dividend														$ 11,000
Warrants issued | shares														213,333
Warrant [Member] | Senior Secured Convertible Promissory Note April 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Short-term Debt [Line Items]
Warrants and Rights Outstanding, Measurement Input														0.92	0.89
Warrant [Member] | Senior Secured Convertible Promissory Note April 2021 [Member] | Measurement Input, Price Volatility [Member]
Short-term Debt [Line Items]
Warrants and Rights Outstanding, Measurement Input														247.52	240.64
Warrant [Member] | Senior Secured Convertible Promissory Note - June 2021 [Member]
Short-term Debt [Line Items]
Interest expense																							5,800
Debt instrument, convertible, conversion price | $ / shares																										$ 0.05
Warrants and Rights Outstanding, Term											6 months 25 days			7 months 6 days
Debt discount to be amortized														$ 37,916
Debt discount														$ 15,784									27,800
Warrants to purchase common stock | shares																										506,667
Deemed dividend											$ 25,000
Warrants issued | shares											213,333
Class of warrant or right, exercise price of warrants or rights | $ / shares											$ 0.075															$ 0.05
Warrant [Member] | Senior Secured Convertible Promissory Note - June 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Short-term Debt [Line Items]
Warrants and Rights Outstanding, Measurement Input											0.81			0.48
Warrant [Member] | Senior Secured Convertible Promissory Note - June 2021 [Member] | Measurement Input, Price Volatility [Member]
Short-term Debt [Line Items]
Warrants and Rights Outstanding, Measurement Input											209			302.11
Warrant [Member] | Secured Convertible Promissory Note - August 11, 2021 [Member]
Short-term Debt [Line Items]
Warrants and Rights Outstanding, Term											1 year
Debt discount to be amortized											$ 56,454
Unamortized Debt Issuance Expense											$ 30,000
Class of warrant or right, exercise price of warrants or rights | $ / shares											$ 0.095
Warrant [Member] | Secured Convertible Promissory Note - August 11, 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Short-term Debt [Line Items]
Warrants and Rights Outstanding, Measurement Input											0.81
Warrant [Member] | Secured Convertible Promissory Note - August 11, 2021 [Member] | Measurement Input, Price Volatility [Member]
Short-term Debt [Line Items]
Warrants and Rights Outstanding, Measurement Input											253
Warrant [Member] | Secured Convertible Promissory Note - August 17, 2021 [Member]
Short-term Debt [Line Items]
Warrants and Rights Outstanding, Term											1 year
Debt discount to be amortized											$ 62,220
Unamortized Debt Issuance Expense											$ 30,000
Class of warrant or right, exercise price of warrants or rights | $ / shares											$ 0.095
Warrant [Member] | Secured Convertible Promissory Note - August 17, 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Short-term Debt [Line Items]
Warrants and Rights Outstanding, Measurement Input											0.77
Warrant [Member] | Secured Convertible Promissory Note - August 17, 2021 [Member] | Measurement Input, Price Volatility [Member]
Short-term Debt [Line Items]
Debt Conversion, Converted Instrument, Rate		24.00%
Warrants and Rights Outstanding, Measurement Input											254
Warrant [Member] | Secured Convertible Promissory Note Two [Member]
Short-term Debt [Line Items]
Debt discount																							377,269
Loss on fair value of derivative liabilities																							4,100,000
Derivative liabilities																							2,000,000
Derivative expense																							1,593,978
Warrant [Member] | Secured Convertible Promissory Note - October 4, 2021 [Member]
Short-term Debt [Line Items]
Debt discount to be amortized							15,000
Unamortized Debt Issuance Expense							$ 32,109
Class of warrant or right, exercise price of warrants or rights | $ / shares							$ 0.095
Warrant [Member] | Secured Convertible Promissory Note October 7, 2021 [Member]
Short-term Debt [Line Items]
Class of warrant or right, exercise price of warrants or rights | $ / shares						$ 0.095
Common Stock [Member]
Short-term Debt [Line Items]
Conversion of convertible debt																							20,000
Common Stock [Member] | Secured Convertible Promissory Note - August 11, 2021 [Member]
Short-term Debt [Line Items]
Debt discount to be amortized											$ 17,041
Common Stock [Member] | Secured Convertible Promissory Note - August 17, 2021 [Member]
Short-term Debt [Line Items]
Debt discount to be amortized											$ 17,209
Stock Issued During Period, Shares, New Issues | shares											112,601
Common Stock [Member] | Secured Convertible Promissory Note - October 4, 2021 [Member]
Short-term Debt [Line Items]
Debt discount to be amortized							$ 77,891
Common Stock [Member] | Secured Convertible Promissory Note October 7, 2021 [Member]
Short-term Debt [Line Items]
Debt discount to be amortized									33,483
Eight Convertible Notes [Member]
Short-term Debt [Line Items]
Principal amount																							1,300,000
Convertible Debt [Member]
Short-term Debt [Line Items]
Debt instrument, convertible, conversion price | $ / shares																										$ 0.05
Debt conversion amount																							$ 554,000
Commitment fee | shares																							3,366,012
Debt Instrument, Periodic Payment																							$ 168,300
Loss on extinguishment of debt																							386,000
Loss on fair value of derivative liabilities																							245,000
Gain on extinguishment of debt																							245,000
Conversion of convertible debt																							141,000
Convertible Debt [Member] | Senior Secured Convertible Promissory Note [Member]
Short-term Debt [Line Items]
Debt Issuance Costs, Net																								14,000
Interest expense																							11,000	5,000
Amortization of Debt Issuance Costs																								70,000
Debt instrument, convertible, conversion price | $ / shares																				$ 0.02
Debt Conversion, Converted Instrument, Rate																				65.00%
Debt default interest rate																			18.00%
Convertible, Beneficial Conversion Feature																				$ 50,000
Beneficial Conversion Feature																				203,000
Accrued interest																							16,000
Convertible Debt [Member] | Secured Convertible Promissory Note [Member]
Short-term Debt [Line Items]
Principal amount																							$ 58,055
Debt instrument, interest rate																							140.00%
Premimum Description																							The 40% premium will be recorded once a demand occurs
Convertible Debt [Member] | Senior Secured Convertible Promissory Note One [Member]
Short-term Debt [Line Items]
Debt Issuance Costs, Net																		4,000
Debt discount																		$ 5,000
Convertible Debt [Member] | Secured Convertible Promissory Note - August 11, 2021 [Member]
Short-term Debt [Line Items]
Debt discount to be amortized											$ 106,505
Convertible Debt [Member] | Secured Convertible Promissory Note - August 17, 2021 [Member]
Short-term Debt [Line Items]
Debt instrument, convertible, conversion price | $ / shares		$ 0.05
Debt discount to be amortized											$ 100,571
Warrants to purchase common stock | shares		720,000
Class of warrant or right, exercise price of warrants or rights | $ / shares		$ 0.05
Convertible Debt [Member] | Secured Convertible Promissory Note October 7, 2021 [Member]
Short-term Debt [Line Items]
Debt discount to be amortized									$ 76,517
Convertible Note [Member] | Senior Secured Convertible Promissory Note [Member]
Short-term Debt [Line Items]
Principal amount																				58,055
Debt Issuance Costs, Net																				$ 14,000
Debt instrument, interest rate																				10.00%
Debt maturity date																				Dec. 26, 2020
Debt Instrument, Interest Rate, Effective Percentage																				10.00%
Debt discount to be amortized																				$ 5,555
Proceeds from issuance of secured debt																				$ 52,500
Registration Rights Agreement [Member] | Secured Convertible Promissory Note - August 11, 2021 [Member]
Short-term Debt [Line Items]
Commitment fee | shares											100,000
Registration Rights Agreement [Member] | Secured Convertible Promissory Note - August 17, 2021 [Member]
Short-term Debt [Line Items]
Commitment fee | shares									100,000
Registration Rights Agreement [Member] | Secured Convertible Promissory Note - October 4, 2021 [Member]
Short-term Debt [Line Items]
Commitment fee | shares							59,523
Registration Rights Agreement [Member] | Secured Convertible Promissory Note October 7, 2021 [Member]
Short-term Debt [Line Items]
Commitment fee | shares						59,523
Debt Conversion, Converted Instrument, Warrants or Options Issued | shares						52,632
Accredited Investors [Member] | Term Loan Subscription Agreements [Member]
Short-term Debt [Line Items]
Principal amount																									$ 5,700,000					$ 5,700,000
Debt Issuance Costs, Net																									$ 707,000
Debt instrument, interest rate																									12.00%
Debt instrument, interest during period																									15.00%
Debt maturity date																							Jun. 28, 2020
Interest expense																							$ 852,000	1,200,000
Amortization of Debt Issuance Costs																								347,000
Accured interest																							2,000,000
Repayments of Debt																							5,700,000
Accredited Investors [Member] | Securities Purchase Agreement [Member]
Short-term Debt [Line Items]
Principal amount																						$ 550,500
Debt instrument, interest rate																						10.00%							18.00%
Debt maturity date																						Aug. 5, 2020
Convertible Notes Payable, Current																						$ 499,950
Debt Instrument, Interest Rate, Effective Percentage																						10.00%
Debt instrument, convertible, conversion price | $ / shares																					$ 0.50
Weighted average Percentage																					70.00%
Debt Conversion, Converted Instrument, Rate																					60.00%
Stock combinations | $ / shares																					$ 0.05
Debt discount to be amortized																						$ 381,000
Accredited Investors [Member] | Securities Purchase Agreement [Member] | Warrant [Member]
Short-term Debt [Line Items]
Warrants and Rights Outstanding, Term																						5 years
Debt discount to be amortized																						$ 322,000
Accredited Investors [Member] | Securities Purchase Agreement [Member] | Convertible Debt [Member]
Short-term Debt [Line Items]
Interest expense																							96,000	75,000
Amortization of Debt Issuance Costs																						38,000		38,000
Debt discount																						21,000		$ 381,000
Accredited Investors [Member] | Securities Purchase Agreement [Member] | Convertible Debt [Member] | Warrant [Member]
Short-term Debt [Line Items]
Debt Issuance Costs, Net																						53,000
Debt discount																						$ 30,000
Accredited Investors [Member] | Securities Purchase Agreement [Member] | Convertible Note [Member]
Short-term Debt [Line Items]
Principal amount																							457,359
Accured interest																							$ 101,000
Debt conversion amount	$ 31,150						$ 26,250	$ 32,500		$ 25,000			$ 27,500			$ 25,900
Commitment fee | shares	623,012						525,000	650,000		500,000			550,000			518,000
Premimum Description																							The 40% premium will be recorded once a demand occurs.
Holders [Member] | Securities Purchase Agreement [Member] | Convertible Note [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate																							140.00%

Licensing Agreements (Details N

Licensing Agreements (Details Narrative) - USD ($)	Dec. 23, 2019	Mar. 16, 2018	May 31, 2018	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2020
Other income					$ 45,000
Novosom Verwaltungs GmbH [Member] | Intellectual Property [Member]
Stock Issued During Period, Shares, Purchase of Assets			51,988
Stock Issued During Period, Value, Purchase of Assets			$ 75,000
Proceeds from Sale of Intangible Assets	$ 45,000
Novosom Verwaltungs GmbH [Member] | Intellectual Property [Member] | Upon Execution of Agreement [Member]
Payables on intellectual property	$ 20,000
Novosom Verwaltungs GmbH [Member] | Intellectual Property [Member] | Achievement of Performance Obligation [Member]
Payables on intellectual property						$ 25,000
Les Laboratories Servier License Agreement [Member]
Payments for royalties				0	0
Novosom Agreement [Member]
Other income					$ 45,000
Revenues				$ 0
License Of DiLA Assets [Member] | Accrued Liabilities [Member]
Upfront payment agreement for license agreement		$ 200,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Due to Related Parties	$ 4,000	$ 4,000
Officers And Directors [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Due from related parties	$ 42,000

Schedule of Stockholders_ Equit

Schedule of Stockholders’ Equity Note, Warrants or Rights (Details)	Dec. 31, 2021shares
Class of Stock [Line Items]
Warrant shares	74,625,139
Warrant [Member]
Class of Stock [Line Items]
Warrant shares	74,625,139
Expiring in 2023	33,504,180
Expiring in 2024	2,807,832
Expiring in 2025	32,921,787
Expiring in 2026	5,391,340
Convertible Notes [Member]
Class of Stock [Line Items]
Warrant shares	40,782,306
Expiring in 2023
Expiring in 2024	2,472,380
Expiring in 2025	32,918,586
Expiring in 2026	5,391,340
Other [Member]
Class of Stock [Line Items]
Warrant shares	348,733
Expiring in 2023	10,080
Expiring in 2024	335,452
Expiring in 2025	3,201
Expiring in 2026
Series E Preferred Stock [Member]
Class of Stock [Line Items]
Warrant shares	30,405,600
Expiring in 2023	30,405,600
Expiring in 2024
Expiring in 2025
Expiring in 2026
Series F Preferred Stock [Member]
Class of Stock [Line Items]
Warrant shares	3,088,500
Expiring in 2023	3,088,500
Expiring in 2024
Expiring in 2025
Expiring in 2026

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative)	Dec. 06, 2021USD ($)shares	Nov. 23, 2021USD ($)shares	Nov. 04, 2021USD ($)shares	Oct. 15, 2021USD ($)shares	Oct. 12, 2021USD ($)shares	Oct. 08, 2021USD ($)shares	Oct. 05, 2021USD ($)shares	Oct. 04, 2021USD ($)shares	Oct. 04, 2021USD ($)shares	Sep. 22, 2021USD ($)shares	Aug. 18, 2021USD ($)shares	Aug. 11, 2021USD ($)shares	Jul. 30, 2021USD ($)shares	Jun. 08, 2021USD ($)shares	Mar. 19, 2021USD ($)$ / sharesshares	Dec. 21, 2020USD ($)shares	Dec. 11, 2020USD ($)shares	Oct. 30, 2019USD ($)shares	Dec. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares	Nov. 30, 2021$ / sharesshares	Jun. 25, 2021$ / shares	Dec. 31, 2019shares	Jul. 31, 2018shares	Apr. 30, 2018shares	Aug. 31, 2015shares	Mar. 31, 2014shares
Class of Stock [Line Items]
Preferred Stock, Shares Authorized																			100,000	100,000
Stated value per share | $ / shares																			$ 0.01	$ 0.01
Warrant exercise price per share | $ / shares																			$ 0.05		$ 0.05	$ 0.08
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			250,000																		131,667
Value of converted shares | $																			$ 554,000
Warrants outstanding																			74,625,139
Stock Issued During Period, Value, Conversion of Convertible Securities | $																			$ 554,000
Loss on extinguishment of debt | $																			$ 386,000
February 2020 Convertible Note [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities																			3,366,012
Stock Issued During Period, Value, Conversion of Convertible Securities | $																			$ 98,141
Interest Expense, Debt | $																			$ 70,160
Convertible Notes [Member]
Class of Stock [Line Items]
Number of warrants issued																			250,000
Banking Agreement [Member]
Class of Stock [Line Items]
Stock issued during period, shares, new issues										300,148
Fair value | $										$ 39,290
Convertible Note Investor [Member]
Class of Stock [Line Items]
Stock issued during period, shares, new issues						59,523			59,523		100,000	100,000
Fair value | $						$ 12,233			$ 10,859		$ 62,220	$ 56,464
Series F Preferred Stock [Member]
Class of Stock [Line Items]
Warrants outstanding																			3,088,500
Series E Warrants [Member]
Class of Stock [Line Items]
Conversion of stock, amount converted | $															$ 25,900
Conversion of stock, shares converted															518,000
Number of warrants issued																			75,000
Series E Warrants [Member] | Maximum [Member]
Class of Stock [Line Items]
Warrant exercise price per share | $ / shares															$ 0.50
Series E Warrants [Member] | Minimum [Member]
Class of Stock [Line Items]
Warrant exercise price per share | $ / shares															$ 0.05
Series E Preferred [Member]
Class of Stock [Line Items]
Conversion of stock, amount converted | $													$ 250,000
Conversion of stock, shares converted		15			5	4	30	20					50	8
Accrued dividends | $														$ 10,000
Number of shares in accrued dividends														101,010
Stock issued during period, shares, new issues		193,299			64,312	51,414	385,414	255,540					500,000	53,571
Common stock for a cashless exercise														75,000
Fair value | $		$ 21,649			$ 7,156	$ 5,707	$ 42,707	$ 27,770
Common Stock [Member]
Class of Stock [Line Items]
Conversion of stock, shares converted													500,000
Stock Issued During Period, Shares, Conversion of Convertible Securities																			3,366,012
Stock Issued During Period, Value, Conversion of Convertible Securities | $																			$ 20,000
Series F Warrants [Member]
Class of Stock [Line Items]
Value of converted shares | $															$ 25,900
Number of shares issued upon conversion															518,000
Series F Warrants [Member] | Maximum [Member]
Class of Stock [Line Items]
Warrant exercise price per share | $ / shares															$ 0.50
Series F Warrants [Member] | Minimum [Member]
Class of Stock [Line Items]
Warrant exercise price per share | $ / shares															$ 0.05
Series F Preferred [Member]
Class of Stock [Line Items]
Conversion of stock, shares converted				3
Stock issued during period, shares, new issues				37,043
Fair value | $				$ 3,521
Series E Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Conversion of stock, shares converted																10	10
Stock issued during period, shares, new issues																121,480	121,699
Fair value | $																$ 60,740	$ 60,850
Warrant [Member]
Class of Stock [Line Items]
Warrants outstanding																			74,625,139
Adjustable warrants, shares																			74,276,406
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations																			343,750
Warrant [Member] | Convertible Note Investor [Member]
Class of Stock [Line Items]
Stock issued during period, shares, new issues			153,227
Fair value | $			$ 250,000
Warrant [Member] | Convertible Note Investor [Member] | Banking Agreement [Member]
Class of Stock [Line Items]
Stock issued during period, shares, new issues	96,091
Fair value | $	$ 18,745
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock designated, shares																			1,000
Series A Junior Participating Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock designated, shares																			90,000
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized																			1,200	1,200
Preferred stock designated, shares																											1,200
Preferred stock, shares outstanding																			100	100
Stated value per share | $ / shares																			$ 0.01	$ 0.01
Preferred stock shares issued																			100	100
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized																			220	220
Preferred stock designated, shares																										220
Preferred stock, shares outstanding																			40	40
Stated value per share | $ / shares																			$ 0.01	$ 0.01
Preferred stock shares issued																			40	40
Series E Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized																			3,500	3,500
Preferred stock designated, shares																									3,500
Preferred stock, shares outstanding																			3,326	3,458
Stated value per share | $ / shares																			$ 0.01	$ 0.01
Preferred stock shares issued																			3,326	3,458
Series F Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized																			2,200	2,200
Preferred stock designated, shares																								2,200
Preferred stock, shares outstanding																			358	361
Stated value per share | $ / shares																			$ 0.01	$ 0.01
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																		150,000
Stock Repurchased During Period, Shares																		20
Stock Repurchased During Period, Value | $																		$ 100,000
Value of warrants held | $																		$ 100,000
Accrued dividends | $																			$ 488,000	$ 347,000
Preferred stock shares issued																			358	361
Series G Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized																			6,000	6,000
Preferred stock designated, shares																							6,000
Preferred stock, shares outstanding																			0	0
Stated value per share | $ / shares																			$ 0.01	$ 0.01
Preferred stock shares issued																			0	0
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares outstanding																			100	100
Stated value per share | $ / shares																			$ 5,000
Preferred stock liquidation preference per share | $ / shares																			$ 5,100
Preferred Stock, Voting Rights																			voting rights of 666.67 votes per share
Common stock at a conversion price, per share | $ / shares																			$ 7.50
Series D Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares outstanding																			40	40
Stated value per share | $ / shares																			$ 5,000
Preferred stock liquidation preference per share | $ / shares																			$ 300
Preferred Stock, Voting Rights																			voting rights of 1,250 votes per share
Common stock at a conversion price, per share | $ / shares																			$ 4
Preferred stock stated dividend rate																			5.00%
Series E Convertible Preferred Stock and Warrants [Member]
Class of Stock [Line Items]
Stated value per share | $ / shares																			$ 5,000
Common stock at a conversion price, per share | $ / shares																			$ 0.50
Preferred stock stated dividend rate																			8.00%
Antidilution price protection expiration date																			Feb. 10, 2020
Series E Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares outstanding																			3,326	3,458
Warrant exercise price per share | $ / shares																			$ 0.05
Deemed dividend | $															$ 390,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																			30,405,600
Accrued dividends | $																			$ 5,000,000	$ 3,700,000
Warrants outstanding																			30,405,600
Series E Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member]
Class of Stock [Line Items]
Fair value of warrants measurement inputs															0.16
Series E Preferred Stock [Member] | Measurement Input, Price Volatility [Member]
Class of Stock [Line Items]
Fair value of warrants measurement inputs															262.27
Series E Preferred Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Warrant term															5 months 4 days
Series E Preferred Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Warrant term															4 months 28 days
Series F Convertible Preferred Stock and Warrants [Member]
Class of Stock [Line Items]
Stated value per share | $ / shares																			$ 5,000
Common stock at a conversion price, per share | $ / shares																			$ 0.50
Preferred stock stated dividend rate																			8.00%
Antidilution price protection expiration date																			Feb. 10, 2020
Series F Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares outstanding																			358	361
Deemed dividend | $															$ 31,000
Warrants outstanding																			3,088,500
Series F Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member]
Class of Stock [Line Items]
Fair value of warrants measurement inputs															0.16
Series F Preferred Stock [Member] | Measurement Input, Price Volatility [Member]
Class of Stock [Line Items]
Fair value of warrants measurement inputs															262.27
Series F Preferred Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Warrant term															6 months 10 days
Series F Preferred Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Warrant term															5 months 15 days
Series G Convertible Preferred Shares [Member]
Class of Stock [Line Items]
Stated value per share | $ / shares																			$ 5,000
Common stock at a conversion price, per share | $ / shares																			$ 0.50
Preferred stock stated dividend rate																			8.00%
Series G Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares issued																			0

Schedule of Share Based Payment

Schedule of Share Based Payments Arrangement, Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Options Outstanding Beginning	391,350	4,071,333
Options outstanding, weighted average exercise price, beginning	$ 1	$ 0.58
Options expired / forfeited	(7,300)	(3,679,983)
Options expired/forfeited, weighted average exercise price	$ 1.83	$ 0.53
Options Outstanding Ending	384,050	391,350
Options outstanding, weighted average exercise price, ending	$ 0.97	$ 1
Options Exercisable	384,050
Exercisable, weighted average exercise price	$ 0.97

Schedule of Share Based Payme_2

Schedule of Share Based Payment Arrangement, Option, Exercise Price Range (Details) shares in Thousands	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding | shares	384,050
Weighted- Average Remaining Contractual Life (Years)	1 year 3 months 25 days
Weighted average exercise price	$ 0.97
Number exercisable | shares	384,050
Weighted average exercise price	$ 0.97
Range One [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise prices, lower	0.98
Range of exercise prices, upper	$ 1
Number outstanding | shares	383,500
Weighted- Average Remaining Contractual Life (Years)	1 year 3 months 29 days
Weighted average exercise price	$ 0.98
Number exercisable | shares	383,500
Weighted average exercise price	$ 0.98
Range Two [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise prices, upper	$ 1.70
Number outstanding | shares	4,050
Weighted- Average Remaining Contractual Life (Years)	7 days
Weighted average exercise price	$ 1.70
Number exercisable | shares	4,050
Weighted average exercise price	$ 1.70

Stock Incentive Plans (Details

Stock Incentive Plans (Details Narrative) - Share-based Payment Arrangement, Option [Member] - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Expense	$ 0	$ 8,000
Share based compensation options outstanding exercisable	$ 0.07

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	Aug. 24, 2021	Jul. 28, 2021	Oct. 30, 2019	Nov. 17, 2021	Nov. 30, 2021	Nov. 04, 2021
Loss Contingencies [Line Items]
Warrants to purchase shares of common stock					131,667	250,000
Melior Pharmaceuticals [Member]
Loss Contingencies [Line Items]
License agreement commitments description				the Company’s timeline from 120 days to 180 days from the effective of the agreement for the Company to raise $4.0 million dollars unless, by 180 Days Adhera is in the process of completing transactions to complete the fundraising then an additional 30 Days shall be provided to allow for the completion of required fundraising
Licensing Agreement MLR1019 [Member]
Loss Contingencies [Line Items]
Debt Instrument, Periodic Payment		$ 21,800,000
Gross sales percentage		5.00%
Option purchase percentage		10.00%
Royalty gross sales percentage		2.50%
Licensing Agreement MLR1019 [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Gross sales percentage	8.00%
Licensing Agreement MLR1019 [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Gross sales percentage	1200.00%
Licensing Agreement MLR1023 [Member]
Loss Contingencies [Line Items]
Debt Instrument, Periodic Payment	$ 21,800,000
License agreement commitments description	if the Company failed to raise $4.0 million dollars within 120 days of the Effective Date then the License would immediately terminate unless, by 120 Days Adhera was in the process of completing transactions to complete the fundraising then an additional 30 Days would be provided to allow for the completion of the raise
Series F Convertible Preferred Stock [Member]
Loss Contingencies [Line Items]
Number of shares repurchased			20
Warrants to purchase shares of common stock			150,000
Stock repurchase			$ 100,000
Value of warrants held			$ 100,000

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 8,402	$ 7,741
Inventory reserve		114
Depreciation and amortization	1,272	2,226
Share based compensation	647	599
Other	613	297
Total deferred tax assets	10,935	10,977
Valuation allowance	(10,935)	(10,977)
Net deferred tax assets
Deferred tax liabilities:
Intangible assets
Net deferred tax liabilities

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Net operating loss carry-forwards	$ 326
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 42,000	$ 0.6

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Mar. 15, 2022	Feb. 16, 2022	Jan. 27, 2022	Dec. 31, 2021	Dec. 31, 2020	Jan. 05, 2022	Jan. 02, 2022	Nov. 30, 2021
Subsequent Event [Line Items]
Debt conversion, converted instrument, amount				$ 554,000
Debt instrument, convertible, conversion price								$ 0.05
Payments of Debt Issuance Costs				101,000	$ 114,000
Convertible Debt [Member]
Subsequent Event [Line Items]
Debt conversion, converted instrument, amount				$ 554,000
Debt instrument, convertible, conversion price								$ 0.05
Debt interest amount, conversion of common stock, shares				3,366,012
Debt periodic payment				$ 168,300
Subsequent Event [Member]
Subsequent Event [Line Items]
Interest rate	10.00%
Payments of Debt Issuance Costs	$ 20,000
Guaranteed Interest Contracts	25,000
Debt periodic payment	$ 39,285.71
Subsequent Event [Member] | Investor [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues	50,000
Subsequent Event [Member] | Licensing Agreement [Member]
Subsequent Event [Line Items]
License agreement commitments description		On February 16, 2022, an addendum to the licensing agreement dated August 4, 2021, was executed by the Company and Melior Pharmaceuticals I, Inc, extending the requirement by the Company to raise $4.0 million dollars to June 16, 2022
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Convertible Redeemable Note [Member]
Subsequent Event [Line Items]
Interest rate	10.00%
Principal amount	$ 250,000
Proceeds from Convertible Debt	200,000
Payments of Debt Issuance Costs	50,000
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Convertible Redeemable Note [Member] | Institutional Investor [Member]
Subsequent Event [Line Items]
Proceeds from Convertible Debt	$ 180,000
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Debt interest amount, conversion of common stock, shares			254,401
Subsequent Event [Member] | Convertible Debt [Member]
Subsequent Event [Line Items]
Interest rate						16.00%	16.00%
Debt conversion, converted instrument, amount			$ 9,500
Principal amount			$ 421
Debt instrument, convertible, conversion price			$ 0.039